Protocol 0167,  Version 1.0, 16APR2018  
Revefenacin  Page 1 of 70 
CLINICAL STUDY PROTOCOL  
Study Title:  A Phase 3b, 42 -day, Randomized, Double -Blind, 
Placeboâˆ’Controlled, Parallel Group Study to Evaluate the 
Safety and Tolerability of Nebulized Revefenacin and 
Nebulized Formoterol Fumarate  
Administered in Sequence and as a Combined Solution in 
Subjects with Chronic Obstructive Pulmonary Disease 
Study Short Title:  A 42-day Parallel Group Safety Study of Revefenacin and 
Formoterol, administered in Sequence and as a Combination, in Subjects with COPD  
Sponsor Study No.:  0167 
Date: 16 April 2018 , Amendment 1  
Test Product:  Revefenacin   
US IND:  
Sponsor:  Theravance Biopharma Ireland Limited  
Connaught House 1 Burlington Road Dublin 4  D04 C5Y6 Ireland 
Telephone: +353 1 539 4800 Facsimile:  +353 1 539 4800 
US contact numbers 
Telephone:  +1 (650) 808 -6000 
Facsimile:  +1 (650) 808 -6464 
Clinical Study Director:  
 
Therav
ance Biopharma US, Inc.  
Telephone:   
This study will be conducted according to the principles of Good Clinical Practice. 
CONFIDENTIAL  
This document is confidential and property of Theravance Biopharma, Inc. It may not be 
copied or provided to any other party without the express written consent of 
Theravance Biopharma, Inc. 
Â© Theravance Biopharma, Inc. (Unpublished Work) . All rights reserved.  

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 2 of 70 
Confide
ntial â€“ Property of Theravance Biopharma, Inc.  PROTOCOL SYNOPSIS  
Study Number and Title:  A Phase 3b, 42-day, Randomized, Double-Blind, 
Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of 
Nebulized Revefenacin and Nebulized Formoterol Fumarate  
Administered in Sequence and as a Combined Solution in Subjects with Chronic 
Obstructive Pulmonary Disease 
Study Short Title:  A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, 
administered in Sequence and as a Combination, in Subjects with COPD  
Estimated Number of Study Centers and Countries or Regions:   Approximately 
 in the United States  
Background and Rationale:   
 
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 3 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Objectives:   The primary objective of the study is: 
â€¢ To characterize the safety and tolerability of once-daily revefenacin inhalation 
solution when dosed sequentially with twice- daily formoterol inhalation solution 
compared to monotherapy formoterol , in a population of patients with 
moderate- to-very severe CO PD over 21 days .  
The secondary objective of this study is: 
â€¢ To characterize the safety and tolerability of dosing a mixture of revefenacin 
inhalation solution  and formoterol compared to dosing a mixture of placebo and 

3URWRFRO$PHQGPHQW 9HUVLRQ$35
5HYHIHQDFLQ 3DJHRI
&RQILGHQWLDOÂ±3URSHUW\RI7 KHUDYDQFH%LRSKDUPD,QFIRUPRWHUROLQDSRSXOD WLRQRISDWLHQWVZLWKP RGHUDWHWRYHU\VH YHUH&23'RYHU
GD\V
7KHH[SORUDWRU\REMHFWLYHVRIWKHVWXG\DUH
x 
6WXG\'HVLJQ 7KLVLVDUDQGRPL]HGGRXEOH EOLQGSODFHERFRQWUROOHGSDUDO OHOJURXS
VWXG\
(DFKVXEMHFWZLOOUHFHLYHWUHDWPHQWWZLFHGDLO\IRUDWRWDORI GD\V7KHUHZLOOEHWZR
WUHDWPHQWJURXSV
7UHDWPHQW*URXS
'D\VWR
5HYHIHQDFLQPFJDQGIRUPRWHUR OPFJVHTXHQWLDOO\DGPLQLVW HUHGYLDQHEXOL]HULQWKH
PRUQLQJ5HYHIHQDFLQZLOOEHD GPLQLVWHUHGILUVWDVDP/VROX WLRQDQGWKHQIRUPRWHURO
ZLOOEHDGPLQLVWHUHGDVDP/ VROXWLRQ)RUPRWHUROZLOOEH DGPLQLVWHUHGDJDLQLQWKH
HYHQLQJ
'D\VWR
$IWHUDGD\SHULRGVXEMHFWV RQUHYHIHQDFLQPFJDQGIRUPR WHUROPFJZLOOEH
GRVHGIRUGD\VZLWKDFRPEL QDWLRQRIUHYHIHQDFLQPFJDQG IRUPRWHUROPFJ
DGPLQLVWHUHGDVDFRPELQHGVRO XWLRQDQGDGPLQLVWHUHGYLDDVLQJ OHQHEXOL]DWLRQDVDP/
VROXWLRQ)RUPRWHUROPFJZ LOOEHDGPLQLVWHUHGDVDP/V ROXWLRQDJDLQLQWKH
HYHQLQJ
7UHDWPHQW*URXS
'D\VWR
3ODFHERUHYHIHQDFLQDQGIRUPRWHURO PFJVHTXHQWLDOO\DGPLQLVW HUHGYLDQHEXOL]HULQWKH
PRUQLQJ3ODFHERZLOOEHDGPLQLVWHUHGILUVWDVDP/VROXWLRQ DQGWKHQIRUPRWHUROZLOOEH
DGPLQLVWHUHGDVDP/VROXWLRQ )RUPRWHUROPFJZLOOEHDG PLQLVWHUHGDVDP/
VROXWLRQDJDLQLQWKHHYHQLQJ
'D\VWR
$IWHUDGD\SHULRGVXEMHFWV RQSODFHERUHYHIHQDFLQDQGIRUPR WHUROPFJZLOOEHGRVHG
IRUGD\VZLWKDFRPELQDWLRQRI SODFHERUHYHIHQDFLQDQGIRUPR WHUROPFJDGPLQLVWHUHG
DVDFRPELQHGVROXWLRQDQGDGPLQLV WHUHGYLDDVLQJOHQHEXOL]DWL RQDVDP/VROXWLRQ
)RUPRWHUROPFJZLOOEHDGPLQLV WHUHGDVDP/VROXWLRQDJD LQLQWKHHYHQLQJ


Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 5 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  All treatments will be administered via a  jet nebulizer using the  
compressor. 
Subj
ects who are currently on a stable dose of inhaled steroids will continue the use of these 
medications throughout the course of the study. 
Subjects who are currently using LABA monotherapy (other than formoterol) will be 
switched to formoterol for the duration of the study . Those subjects on ICS/LABA fixed 
dose combinations must be able to switch to an identical dose of ICS monotherapy 
(or equivalent) to be eligible to enroll in the study.  
Screening wi ll involve either one or two visits, depending on whether a washout period is 
required. The first visit will be an Initial Screening Visit (Visit 1A) when informed consent will be obtained and the subjectâ€™s existing COPD medication will be assessed to decide whether any adjustments are required to comply with the requirements of the protocol. The 
subject will start a washout period only after signing the informed consent form.  
After completing the washout (if required) , the subject will return for further screening 
assessments, including an Ipratropium Reversibility Visit (Visit 1B), electrocardiograms 
(ECGs) and vitals. It is only necessary to conduct the Initial Screening Visit (Visit 1A) and 
Ipratropium Reversibility Visit (Visit 1B) as separate visits if a washout is required. If a 
washout period is not required, these two visits may be performed as one visit.  
If a washout period is required, the time from the Initial Screening Visit (Visit 1A) to 
Visit 1B will be at least 48 hours and no longer than 7 days.  
At the Ipratropium Reversibility Visit (Visit 1B), the FEV
1 response to a nebulized dose of 
ipratropium (500 mcg) will be tested to determine  the subjectâ€™s reversibility  status and  
GOLD category for airflow limitation.   
All remaining inclusion and e xclusion criteria will be reviewed at this Visit 1B  
All subjects will be issued study -specific rescue medication (albuterol metered -dose inhaler 
or MDI) for use throughout the screening period. Subjects will be advised to avoid use of 
their rescue albutero l medication for at least 6 hours prior to each v isit. 
Subjects will come in 2 to 7 days after Screening for Visit 2 (Day 1 of dosing). E ligible 
subjects will be randomized to one of two treatment groups in the study.  
The treatment period will involve 3 visits: 
â€¢ Visit 2 (Day 1)  
â€¢ Visit 3 (Day 2 1) 
â€¢ Visit 4 (Day 42)  
On visit days , subjects will attend the clinic for assessment of pre -dose vital signs, labs, 
ECGs,  and review of AEs and concomitant medications. Subjects 
will admin
ister study medication under supervision at all clinic visits to assess nebulizer 
technique and to correct and retrain as required. ECGs and vital s igns will be measured 
60 minutes pre-dose and 10 minutes post-dose at these visits. 
 

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 6 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.   On all visits, subjects will return the unused vials of 
study medication and the study- specific rescue medication they have been  issued.  
At Visit 3 (Day 21 ), subjects will return for in -clinic dosing and .   
Visit 3 will have a visit window of Â±7 days.  ECGs will be performed after the final 
supervised dose of the sequential administration of revefenacin (or placebo) and then 
formoterol  at 10 minutes postdose, which should be near the peak plasma level of 
formoterol.  The site will instruct the patient on how to mix the two solutions of study 
medication as a combined solution in the nebulizer.  Subjects will a dminister the study 
drugs as a combined solution for the remainder of the treatment period (Day 22 to 42).   
Subjects will return to clinic for Visit 4 (Day 42) for in -clinic supervised dosing  
.  Visit 4 will have a visit window o f Â±7 days. ECGs will be 
performed after the supervised final dose of the combined administration of revefenacin (or 
placebo) plus formoterol at 10 minutes postdose, which should be near the peak plasma 
level of formoterol.   
Visit 5 will be a follow up phone call to take place 7 ( Â±2) days after Visit 4 (Day 42) to 
assess the subject for any adverse events or changes in concomitant medications.  
Subjects who experience moderate or severe acute exacerbations of COPD (AECOPD) will 
not be allowed to continue and will be withdrawn from the study.  
Duration of Study Participation : Up to 63 days  (including screening and any required 
washout period).  
Number of Subjects per Group: Approximately 60 subjects will be enrolled into  each of 
two treatment groups in a blinded 1:1 ratio (total of approximately 120 subjects).  
Study Population:  
Patients with moderate - to-very severe COPD who meet the criteria for study enrollment.  
Inclusion Criteria  
1. Subject is a male or female subject 40 years of age or older (age at Visit 1A).  
2. Subject is willing and able to provide signed and dated written informed consent to participate at Visit 1A prior to initiation of any study related procedures.  
3. Subject is capable of performing reproducible spirometry maneuvers as described 
by current American Thoracic Society (ATS) Guidelines and has a post -ipratropium 
FEV
1/FVC ratio <0.7 at Visit 1B.  
4. Subject has moderate -to-very severe stable COPD with a post -ipratropium FEV 1 
less than 80% of predicted normal at Visit 1B and a post-ipratropium FEV 1 
>700 mL at Visit 1B.  
5. Subject has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack- years. 

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 7 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  6. Subject must be willing and able to attend study visits according to the visit 
schedule and adhere to all study assessments/procedures . 
7. Females of either child bearing potential or non-child bearing potential as follows: 
â€¢ Females of childbearing potential must have documentation of a negative urine 
pregnancy test at Visit 1B and again at Visit 2 (prior to randomization) if Visit 2 
is > 7 days after Visit 1B . If a urine pregnancy test is positive, it must be 
confirmed via a second urine pregnancy test. All female subjects of childbearing 
potential must agree to use a highly effective method of birth control during the 
study and for at least 1 month after completion of study drug dosing.  
âˆ’ A highly effective method of birth control is defined as one that results in a 
low failure rate (i.e., <1% per year) when used consistently and correctly, 
such as condom + diaphragm, condom + spermicide, diaphragm + 
spermicide, or intrauterine device [IUD] with documented failure rate of 
<1% per year, or oral/injectable/implanted hormonal contraceptives used in combination with an additional barrier method.  
âˆ’ Females are considered to be not of childbearing potential if they have had a 
total hysterectomy and/or bilateral tubal ligation (documentation for either must be provided before enrollment) or are at least 2 years postmenopausal (>24 months since last menstrual period).  
Exclusion Criteria:  
1. Females who are pregnant, planning to become pregnant, or breastfeeding during the study. 
2. Subject has a significant respiratory disease or disorder other than COPD that, in the 
opinion of the investigator, would interfere wit h the interpretation of data from this 
study including, but not limited to , restrictive lung disorders, benign or malignant 
tumors of the lung, chronic pulmonary infections such as tuberculosis, occupational lung disease such as silicosis or asbestosis, inflammatory disorders of the lung, 
alpha-1-antitrypsin deficiency, and/or abnormalities of the chest wall or musculature (e.g., scoliosis, myasthenia gravis, phrenic nerve palsy).  
3. Subject has a history of cancer of any organ, treated or untreated in the 5 years prior 
to Visit 1A (excludes localized basal cell or squamous cell carcinoma of the skin; localized prostate cancer in situ of grade 1; localized cervical cancer in situ of 
grade 0). 
4. Subject has a concurrent disease or condition that, in the opinion of the investigator, 
would interfere with study participation or confound the evaluation of safety, 
tolerability, or pharmacokinetics of the study drug. 
5. Subject has a history of reactions or hypersensitivity to inhaled or nebulized 
anticholinergics, short-a cting beta -agonists and long- acting beta -agonists. 
Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 8 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  6. Subject suffers from any medical condition that would preclude the use of inhaled 
anticholinergics, including narrow -angle glaucoma, symptomatic benign prostatic 
hyperplasia, bladder neck obstruction, or urinary retention. 
7. Subject has a significantly increased risk of cardiovascular events, as assessed by 
the investigator , and indicated by a history at Visit 1A of myocardial infarction or 
unstable angina within the last 6  months, new , unstable or life threa tening cardiac 
arrhythmia requiring intervention in the last 6 months, or New York Heart 
Association (NYHA) Class IV heart failure.  
8. Subjects with clinically significant and uncontrolled hypertension, 
hypercholesterolemia or Type II diabetes mellitus , as assessed by the investigator . 
9. Subject has been hospitalized for COPD or pneumonia within 8 weeks prior to 
Visit 1B. 
10. Subject has used systemic corticosteroids within 8 weeks prior to Visit 1B.  
11. Subject has used antibiotics for respiratory tract infections within 8 weeks prior to 
Visit 1B. 
12. Subject is unwilling or unable to stop the use of prohibited medications during the washout (if required) and treatment period and follow-up period of the study. 
Test Product, Dose, and Route of Administration; Regimen; Duration of Treatment:   
â€¢ Revefenacin 175 mcg inhalation solution or matching placebo by jet nebulizer 
taken daily (QD) for 42 days. 
Test Product , Dose, and Route of Administration; Regimen ; Duratio n of Treatment:  
â€¢  (formoterol f umarate) 20 mcg administered by jet nebulizer 
taken twice daily (BID) every day for 42 days. 
Reference Therapy, Dose, and Route of Administration; Regimen; Duration of 
Treatment:  
â€¢ Placebo for TD -4208 solution for inhalation by jet nebulizer, QD administration 
every morning for 12 weeks. 
Statistical Methods   
Sample Size:  
A sample size  of n=60 per group was determined to be adequate to assess the safety and 
tolerability of sequential or combination revefenacin with formoterol to monotherapy 
formoterol .  
 
 
 

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 9 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Study Endpoints:  
The primary endpoint(s) of thi s study will assess the long -term safety and tolerability  of 
revefenacin in the treatment of COPD:  
â€¢ Frequency and severity of adverse events, including COPD exacerbations  
â€¢ Vital signs  
â€¢ Clinical laboratory evaluations  
â€¢ 12-lead ECG changes from baseline  
â€¢ Heart rate (as measured by ECG)  
The exploratory endpoints of this study  
 
  
Analys
is: 
All safety data will be presented in listings. Descriptive summary tables will be provided 
for treatment -emergent adverse events, laboratory evaluations, vital signs, 12- lead ECG 
parameters, and concomitant medications.  
 
 
 
 
 
 
 

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 10 of 70 
Confi
dential â€“ Property of Theravance Biopharma, Inc.  SCHEDULE OF STUDY PROCEDURES  
Table 1: Schedule of Study Procedures
Screeninga Randomization 
Day 1 
(Visit 2) Day 21 
(Visit 3) 
(Â± 7 days) Day 42 
(Visit 4) 
(Â± 7 days) Day 49 
(Visit 5) 
Telephone 
Follow Up  
(7 daysÂ± 2 days  
after Visit 4) Early 
Termination/  
Withdrawal  
(Visit 1A)  (Visit 1B)  
Informed Consent  â–  
Medication and Medical 
History â–  
Washout of COPD Medications (as  required) â–  
Physical examination  â–  â–  â–  â–  
Height and Weight  â–  
Vital Signsb â–  â–  â–  â–  â–  
Inclusion/Exclusion Criteria 
Review â–  â–  â–  
Urine Pregnancy Test (Female 
subjects)c â–  â–  â–  â–  
Ipratropium Reversibility d â–  
Randomization  â–  
Dispense study med  â–  â–  
Collect and reconcile returned 
study drug (with compliance 
assessment), and rescue 
medication  â–  â–  â– 
Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 11 of 70 
 
SCHEDULE OF STUDY PROCEDURES  (CONTINUED)  
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Table 1: Schedule of Study Procedures  
 Screeninga Randomization 
Day 1 
(Visit 2) Day 21 
(Visit 3) 
(Â± 7 days) Day 42 
(Visit 4) 
(Â± 7 days) Day 49 
(Visit 5) 
Telephone 
Follow Up  
(7 daysÂ± 2 days  
after Visit 4) Early 
Termination/  
Withdrawal  
(Visit 1A)  (Visit 1B)  
Con Meds  â–  â–  â–  â–  â–  â–  â–  
AEs  â–  â–  â–  â–  â–  â–  
Dispense Rescue Medication 
and training on use   â–    â–  â–     
Dispense Daily diary and train on use
 â–  â–  â–  â–     
Collect and Review Daily Diary (if applicable)   â–  â–  â–  â–   â–  
Hematology and serum 
chemistry    â–  â–  â–   â–  
ECG e  â–  â–  â–  â–    
 
       
 
In-Clinic study drug dosing   â–  â–  â–    

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 12 of 70 
 
SCHEDULE OF STUDY PROCEDURES  (CONTINUED)  
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Table 1: Schedule of Study Procedures  
 Screeninga Randomization 
Day 1 
(Visit 2) Day 21 
(Visit 3) 
(Â± 7 days) Day 42 
(Visit 4) 
(Â± 7 days) Day 49 
(Visit 5) 
Telephone 
Follow Up  
(7 daysÂ± 2 days  
after Visit 4) Early 
Termination/  
Withdrawal  
(Visit 1A)  (Visit 1B)  
Training on the self -
administration of 
revefenacin/placebo and formoterol  (sequentially at 
Visit 2 and combined at 
Visit 3)   â–  â–    
 
 
      
 
Record Study Drug Use and 
Rescue Med Use on Daily 
diaryg   â–  â–  â–   
 
a Visit 1A and 1B will be conducted as one visit unless a washout is required in which case they will be conducted as separate visits.   If a washout period is required, the time 
from the Initial Screening Visit (Visit 1A) to Visit 1B will be at least 48 hours and no longer than 7 days. 
b Vital signs on D ay 1, Day 21, and Day 42 are performed at 60 mins pre -dose and 10 mins post -dose. Subjects need to be resting in a semi -recumbent position approximately  
5 minutes pri or to assessment of vital signs.  
c A repeat urine pregnancy test  is required at randomizat ion (Visit 2)  if visit is > 7 days after visit 1 B urine pregnancy test.  
d   
e ECG will be performed 60 mins pre -dose and 10 mins post -dose at Visits 2, 3, and 4.    
f One session will be done if subject is willing.  
g Recorded by subject on the daily diary every day during the treatment period of the study.  
 

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 13 of 70 
Confi
dential â€“ Property of Theravance Biopharma, Inc.  TABLE OF CONTENTS  
PROTOCOL SYNOPSIS  ............................................................................................ 2  
SCHEDULE OF STUDY PROCEDURES  ............................................................... 10  
LIST OF ABBREVIATION S AND DEFINITION OF TERMS .............................. 18  
1. INTRODUCTION  .................................................................................. 20  
1.1. Background and Rationale ...................................................................... 20  
1.2. Nonclinical Profile .................................................................................. 21  
1.2.1.  Pharmacology  ......................................................................................... 21  
1.2.2.  Toxicology .............................................................................................. 22  
1.3. Clinical Experience ................................................................................. 22  
1.4. Risks and Benefits .................................................................................. 24  
2. OBJECTIVES  ......................................................................................... 25  
3. STUDY DESIGN  ................................................................................... 26  
3.1. Overview  ................................................................................................. 26  
3.2. Rationale for Study Design  ..................................................................... 26  
3.3. Selection of Dose and Duration of Treatment ........................................ 26  
3.4. Study Endpoints  ...................................................................................... 27  
3.5. Minimization of Bias  .............................................................................. 27  
3.5.1.  Blinding .................................................................................................. 27  
3.5.2.  Treatment Assignment  ............................................................................ 28  
4. STUDY POPULATION  ......................................................................... 29  
4.1. Inclusion Criteria  .................................................................................... 29  
4.2. Exclusion Criteria  ................................................................................... 30  
5. STUDY DRUGS  .................................................................................... 31  
5.1. Description of Study Drugs .................................................................... 31  
5.1.1.  Revefenacin and Placebo  ........................................................................ 31  
5.1.2.  Formoterol .............................................................................................. 31  
5.2. Dosage and Administration .................................................................... 31  
5.2.1.  Revefenacin  ............................................................................................ 31  
5.2.2.  Formoterol .............................................................................................. 32  
5.2.3.  Agents for Rescue or Responsiveness Testing ....................................... 32  
5.2.3.1.  Ipratropium ............................................................................................. 32  
Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 14 of 70 
Confide
ntial â€“ Property of Theravance Biopharma, Inc.  5.2.3.2.  Albuterol ................................................................................................. 32  
5.3. Treatment Compliance  ............................................................................ 33  
5.4. Drug Accountability and Reconciliation ................................................ 33  
6. STUDY PROCEDURES  ........................................................................ 34  
6.1. Schedule of Study Procedures ................................................................ 34  
6.2. Total Blood Volume ............................................................................... 34  
6.3. Procedures by Visit  ................................................................................. 34  
6.3.1.  Visit 1A (Screening Visit) â€“ (performed up to 7 days before Visit 1B) . 35  
6.3.2.  Visit 1B â€“ (if a washout is not required Visit 1A and 1B may be 
conducted as one visit) ............................................................................ 36  
6.3.3.  Treatment and Follow-up Period ............................................................ 36  
6.3.3.1.  Visit 2 (Randomization Visit)  ................................................................. 36  
6.3.3.2.  Visit 3 (Day 21 Â± 7  days) ........................................................................ 38  
6.3.3.3.  Visit 4 (D ay 42 Â± 7 days) ........................................................................ 39  
6.3.3.4.  Visit 5 (Telephone Follow-up) (7 Days Â± 2 days after Visit 4)  .............. 39  
6.3.4.  Early Termination  ................................................................................... 39  
6.3.5.  Unscheduled Visits ................................................................................. 40  
6.4. Description of Study A ssessments .......................................................... 40  
6.4.1.  Demographic and Baseline Assessments ................................................ 40  
6.4.2.  Assessments ............................................................................................ 41  
6.4.3.  Safety Assessments  ................................................................................. 41  
6.4.3.1.  Adverse Events  ....................................................................................... 41  
6.4.3.2.  Medical History  ...................................................................................... 41  
6.4.3.3.  Physical Examination  ............................................................................. 41  
6.4.3.4.  Vital Signs  .............................................................................................. 41  
6.4.3.5.  Laboratory Tests  ..................................................................................... 41  
6.4.3.6.  ECG â€“ 12-lead ........................................................................................ 42  
6.4.3.7.  Pregnancy  ............................................................................................... 42  
  
6.5. Concomitant Medications ....................................................................... 42  
6.6. Restrictions  ............................................................................................. 46  
6.7. Discontinuation ....................................................................................... 46  
6.7.1.  Subject Discontinuation .......................................................................... 46  

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 15 of 70 
Confi
dential â€“ Property of Theravance Biopharma, Inc.  6.7.2.  Subject Replacement  .............................................................................. 48  
6.7.3.  Study Discontinuatio n ............................................................................ 49  
6.8. Pregnancy  ............................................................................................... 49  
6.9. COPD Exacerbations  .............................................................................. 49  
7. ADVERSE EVENTS .............................................................................. 50 
7.1. Definitions  .............................................................................................. 50  
7.1.1.  Adverse Events (AE) for the Purposes of This Study ............................ 50  
7.1.2.  Serious Adverse Event (SAE) ................................................................ 51  
7.1.3.  Additional Considerations for Serious Adverse Events ......................... 51  
7.2. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ............................................ 52  
7.3. Assessment of Adverse Events ............................................................... 52  
7.3.1.  Severity ................................................................................................... 52  
7.3.2.  Causal Relationship to Study Medication ............................................... 52  
7.4. AE Reporting and Recording .................................................................. 53  
7.4.1.  AE Reporting .......................................................................................... 53  
7.4.2.  AE and SAE Recording .......................................................................... 53  
7.4.3.  SAE Reporting Timeline  ........................................................................ 54  
7.5. Adverse Event Follow- up ....................................................................... 55  
8. STATISTICAL CONSIDERATIONS  ................................................... 56  
8.1. General Considerations ........................................................................... 56  
8.2. Sample Size and Power  .......................................................................... 56  
8.3. Analysis Sets  ........................................................................................... 56  
8.3.1.  Examination of Subgroups ..................................................................... 57  
8.3.2.  Major Protocol Analysis Deviations ....................................................... 57  
8.4. General Analyses  .................................................................................... 57  
8.4.1.  Demographics Characteristics  ................................................................ 57  
8.4.2.  Screening Summaries  ............................................................................. 57  
8.4.3.  COPD Clinical History and Smoking History  ........................................ 57  
8.4.4.  Select Medical History  ........................................................................... 57  
8.5. Safety Analyses  ...................................................................................... 58  
8.5.1.  Extent of Exposure ................................................................................. 58  
8.5.2.  Adverse Event Data  ................................................................................ 58  
Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 16 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  8.5.3.  Concomitant Medications ....................................................................... 58  
8.5.4.  Laboratory Data  ...................................................................................... 59  
8.5.5.  Vital Signs Data  ...................................................................................... 59  
8.5.6.  ECG Data  ................................................................................................ 59  
8.6. Other Analyses  ........................................................................................ 60  
8.6.1.  Other Endpoints ...................................................................................... 61  
  
  
  
8.6.5.  Multiplicity Adjustment .......................................................................... 62 
8.7. Missing Data Handling  ........................................................................... 62  
8.8. Data Monitoring Committee  ................................................................... 62  
9. STUDY ADMINISTRATION  ............................................................... 63  
9.1. Principal Investigator Responsibilities  ................................................... 63  
9.2. Institutional Review Board/Independent Ethics Committee  .................. 64  
9.3. Informed Consent ................................................................................... 64  
9.4. Data Recording and Quality  Assurance  .................................................. 64  
9.5. Document Retention ............................................................................... 65  
9.6. Confidentiality  ........................................................................................ 66  
9.7. Access to Data and Documents  .............................................................. 66  
9.8. Quality Control: Study Monitoring and Auditing .................................. 67  
9.9. Publication  .............................................................................................. 67  
10. REFERENCES  ....................................................................................... 68  
11. APPENDICES  ........................................................................................ 69  
APPENDIX 1.  PROTOCOL SIGNATURE FORM  ............................................... 70  
 
  

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 17 of 70 
Confide
ntial â€“ Property of Theravance Biopharma, Inc.  LIST OF TABLES  
Table 1:  Schedule of Study Procedures ................................................................ 10  
  
 
Table 3:  Severity Criteria for COPD Exacerbations  ............................................. 48  
Table 4:  Outlier Threshold for Vital Signs  ........................................................... 59  
Table 5:  ECG Test Outlier Thresholds  ................................................................. 60  
LIST OF FIGURES  
Figure 1: Study Design Schema  ............................................................................. 26  

Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 18 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  LIST OF ABBREVIATION S AND DEFINITION OF TERMS 
Abbreviation  Description  
ACh Acetylcholine  
AE adverse event  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
ATS American  Thoracic Society  
BID twice daily  
ANCOVA analysis of covariance  
BMI body mass index 
BP blood pressure  
BUN blood urea nitrogen 
CFR United States Code of Federal Regulations  
COPD chronic obstructive pulmonary disease  
CRF case report form  
CSPV Clinical Safety and Pharmacovigilance  
CV Coefficient of variation  
ECG Electrocardiogram  
eCRF electronic case report form  
EDC electronic data capture 
FDA United States Food and Drug Administration  
FEV1 forced expiratory volume in 1 second 
FVC forced vital capacity  
GCP Good Clinical Practice  
GFR glomelular filtration rate  
GOLD Global Initiative for Crohnic Obstructive Lung Disease  
HR heart rate 
IB Investigator's Brochure  
ICF informed consent form 
ICH International Conference on Harmonization (Technical Requirements for Registration 
of Pharmaceuticals for Human Use)  
ICS Inhaled Corticosteroids  
IEC Independent Ethics Committee  
IQR interquartile range  
IRB Institutional Review Board  
ITT Intent-to-treat 
LABA long-acting beta 2 agonist 
LAMA long-acting muscarinic antagonist  
LTOT Long Term Oxygen Therapy 
Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 19 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  LIST OF ABBREVIATION S AND DEFINITION OF TERMS 
Abbreviation  Description  
  
MedDRA  Medical Dictionary for Regulatory Activities (MedDRAÂ®) 
MDI Metered-dose inhaler  
M1 muscarinic receptor 1 (subtype)  
M2 muscarinic receptor 2 (subtype)  
M3 muscarinic receptor 3 (subtype)  
M4 muscarinic receptor 4  (subtype)  
M5 muscarinic receptor 5 (subtype)  
NYHA New York Heart Association  
Pack Years  Number of packs per day times number of years smoked  
PI principal investigator  
PIFR Peak Inspiratory Flow Rate  
PP per-protocol 
PRN Administration as needed  
PT preferred term  
QD daily 
REB research ethics board  
RTSM randomization and treatment supply management  
QTcB Bazett-corrected QT interval  
QTcF Fridericia -corrected QT interval  
SABA short-acting beta 2 agonist 
SAE serious adverse event  
SAP statistical analysis plan  
SD standard deviation  
sGaw specific airway conductance  
SOC system organ class  
SOP standard operationg procedure  
TBPH Theravance Biopharma, Inc.  
TEAE treatment -emergent adverse event  
 
 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 20 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  1. INTRODUCTION 
Pharmacologic t reatment of chronic obstructive pulmonary disease (COPD) with 
bronchodilators is central to the management of both the symptoms and the long term risks of 
the condition. Long-acting inhaled bronchodilators are convenient and may be more effective 
for long-term symptom relief than short-acting bronchodilators; accord ingly, 
widely-accepted treatment guidelines such as those produced by the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD)  recommend the use of long- acting muscarinic 
antagonist (LAMA) bronchodilators as first- line therapies for subject s with persistent COPD 
symptoms1.  
The use of dual bronchodilation has increasingly been recommended for the treatment of 
COPD. Recent GOLD guidelines have advocated stepping from monotherapy bronchodilator therapy to dual bronchodilator therapy for patients who remain symptomatic. More recently, 
the IMPACT study has demonstrated that triple therapy may have benefit above either 
ICS/LABA therapy or LAMA/LABA therapy.  
1.1. Background and Rationale  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 21 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2. Nonclinical Profile  
Revefenacin  is a novel, long- acting, anti -muscarinic agent being developed as an inhalation 
solution for administration via standard jet nebulizer for the treatment of COPD.  A review of 
the nonclinical profile of revefenacin  can be found in the current version of the revefenacin  
Investigatorâ€™s Brochure (I B). A brief summary of the pertinent findings follows this section. 
 is a long-acting beta- 2 adrenergic receptor agonist that is United States Food 
and Drug Administration ( FDA) approved for the nebulized treatment of COPD. For 
additional information on the efficacy and safety of Inhalation Solution refer to 
prescribing information.    
1.2.1. Pharmacology 
 
 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 22 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.   
 
 
 Over
all, the pharmacology of revefenacin , when 
administered into the lungs, is consistent with that of a long-acting muscarinic antagonist and 
demonstrates good selectivity for lung versus systemic effects .  
Safety pharmacology studies for  revefenacin  included assessments of potential effects on 
cardiovascular and respiratory function and f or potential neurobehavioral effects. These 
studies are summarized in the IB. 
1.2.2. Toxicology 
The toxicology assessment of revefenacin  included single- dose toxicity, repeated -dose 
toxicity, genotoxicity, reproductive and developmental toxicity, and local tolerance studies. The results of these studies are summarized in the IB.  
1.3. Clinical Experience  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 23 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.   
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 24 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  1.4. Risks and Benefits  
Subjects participating in this study may be at risk of experiencing adverse events related to 
muscarinic antagonism, including headache, mouth dryness, constipation, blurred vision, 
dizziness and urinary retention.  
Subjects participating in this study may experience discomfort  due to blood draws for 
laboratory testing.     
Clinically significant bronchodilation has been observed in each of the study populations of 
COPD subjects thus far in the development program. Two replicate phase 3 efficacy studies 
 with a 3-month treatment period have demonstrated that the 88 mcg  and 
175 mcg doses of revefenacin were generally well -tolerated, with comparable rates of 
adverse events and seri ous adverse events across all treatment groups (active and placebo). 
The most commonly reported adverse events, across both trials and across all revefenacin 
treatment groups were COPD exacerbation, nasopharyngitis, cough, dyspnea and headache. 
There were no reports of blurred vision, narrow- angle glaucoma or worsening of urinary 
retention, all of which are commonly reported adverse events for this class of medication. I n 
addition, reports of dry mouth were < 0.5% in the revefenacin treatment arms.  A long term 
safety study with a 1- year treatment period revealed a similar safety profile to what 
was observed to the efficacy studies.  
Further detail regarding the safety profile for revefenacin is available in the revefenacin  IB. 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 25 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  2. OBJECTIVES 
The primary o bjective of the study is as follows:  
â€¢ To characterize the safety and tolerability of once-daily revefenacin inhalation 
solution when dosed sequentially with twice- daily formoterol inhalation solution 
 compared to monotherapy  in a 
population of patients with moderate- to-very severe COPD over 2 1 days.  
The secondary objective of this study is: 
â€¢ To characterize the safety and tolerability of dosing a mixture of revefenacin 
inhalation solution and formoterol compared to dosing a mixtur e of placebo and 
formoterol in a population of patients with moderate- to-very severe COPD over 
21 days.  
The exploratory objectives of the study are:  
â€¢  

3URWRFRO$PHQGPHQW 9HUVLRQ$35
5HYHIHQDFLQ 3DJHRI
&RQILGHQWLDOÂ±3URSHUW\RI7 KHUDYDQFH%LRSKDUPD,QF678'<'(6,*1
2YHUYLHZ
)LJXUH 6WXG\'HVLJQ6FKHPD

5DWLRQDOHIRU6WXG\'HVLJQ
7KLVVWXG\LVGHVLJQHGWRSURYL GHVDIHW\GDWDIRUWKHXVHRIRQ FHGDLO\UHYHIHQDFLQ
DGPLQLVWHUHGVHTXHQWLD OO\ZLWKIRUPRWHUROIRUGD\VWKHQIROO RZHGZLWKGRVLQJDPL[WXUHRI
UHYHIHQDFLQDQGIRUPRWHUR OIRUDQRWKHUGD\V 

7KLVZLOOEHDUDQGRPL]HGGRXEO HEOLQGSODFHERFRQWUROOHGVWX G\WRFKDUDFWHUL]HWKHVDIHW\
DQGWROHUDELOLW\RIUHYHIHQDFLQL QKDODWLRQVROXWLRQDGPLQLVWHUH GYLDDVWDQGDUGMHWQHEXOL]HURU
SODFHERSULRUWRIRUPRWHUROD/$% $WKDWLVFRPPHUFLDOO\DYDLOD EOHIRUQHEXOL]DWLRQ$OO
VXEMHFWVZLOOKDYHDFFHVVWRLQKDO HGDOEXWHUROUHVFXHLQKDOHUV DVUHTXLUHG6XEMHFWVZKRDUHRQ
DVWDEOHGRVHRILQKDOHGFRUWLF RVWHURLGVZLOOEHSHUPLWWHGWRF RQWLQXHWKHXVHRIWKLV
FRQFRPLWDQWPHGLFDWL RQWKURXJKRXWWKHVWXG\
6XEMHFWVZLOOEHUHTXL UHGWRPHHWWKHVWDQGD UGVSLURPHWU\GHILQ LWLRQVIRUPRGHUDWHWRYHU\
VHYHUH&23'SRVW EURQFKRGLODWRU)(9 )9&UDWLRRIDQGD SRVWEURQFKRGLODWRU
)(9RISUHGLFWHGQRUPDOD QGDSRVWEURQFKRGLODWRU)(9 !P/>1+$1(6,,,@
6HOHFWLRQRI'RVHDQG'XUDWLRQRI7UHDWPHQW
7KHVHOHFWLRQRIWKHPFJGRVH RIUHYHIHQDFLQIRUWKLVVWXG\ LVEDVHGRQWKHUHVXOWVRI
WZRWZHOYHZHHNVWXGLHVFRQGXFWH GDVSDUWRIWKHSKDVHSURJUD PLQWKHFOLQLFDO
GHYHORSPHQWRIUHYHIHQDFL Q6WXGLHVDQG7KHUHVXOWV RIWKRVHVWXGLHVVKRZHG
WKDWUHYHIHQDFLQDGPLQLVWHUHGRQF HGDLO\YLDDVWDQGDUGMHWQH EXOL]HUDWGRVHVRIPFJDQG
PFJWRVXEMHFWVZLWKPRGHUDWHW RYHU\VHYHUH&23'GHPRQVWU DWHGFOLQLFDOO\DQG
VWDWLVWLFDOO\VLJQLILFDQW LPSURYHPHQWVLQWURXJK)(9 RYHUWKHHQWLUHWUHDWPHQWSHULRG
5HYHIHQDFLQDWPFJGHPRQVWUDW HGDQGUHSOLFDWH GFRQVLVWHQWO\ JUHDWHULPSURYHPHQWVLQ
)(9DFURVVERWKVWXGLHVLQFRQFRPLWD QW/$%$VXEMHFWVDQGLQPRUH VHYHUHVXEMHFWVWKDQ
UHYHIHQDFLQDWPFJ0RVWFR PPRQ$(VDFURVVDOOWUHDWPHQWJU RXSVZHUHH[DFHUEDWLRQV
FRXJKG\VSQHDDQGKHDGDFKH7KH$(SURILOHGLGQRWGLIIHUIUR PWKHH[SHFWHG
VDIHW\WROHUDELOLW\SU RILOHWRGDWHIRUUHY HIHQDFLQRURWKHU/$ 0$V5HYHIHQDFLQDSSHDUVWREH
VDIHDQGZHOOWROHUD WHGLQWKHSRSXODWLRQRI VXEMHFWVLQWKHVH VWXGLHV

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 27 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  3.4. Study Endpoints   
The primary and secondary endpoints of this study will assess the long- term safety and 
tolerability of revefenacin in the treatment of COPD: 
â€¢ Frequency and severity of adverse events, including COPD exacerbations 
â€¢ Vital signs  
â€¢ Clinical laboratory evaluations  
â€¢ 12-lead ECG changes from baseline   
â€¢ Heart rate (as measured by ECG)  
The exploratory endpoints of this study  
 
  
3.5. Minimization of Bias   
Bias will be minimized through the use of randomization and a double-blind study design , 
with respect to revefenacin and placebo.    
3.5.1. Blinding 
All study subjects, study investigators and their staff, and the Sponsorâ€™s staff involved in the 
conduct of the study will be blinded to treatment assignment with regard to revefenacin and placebo.  Subjects will be assigned in random ord er to revefenacin  or placebo according to 
the randomization schedule. The only personnel who will have access to the randomization schedule before database lock are:  
â€¢ The nominated personnel at the Contract Research Organization responsible for 
generation o f the randomization schedule. 
In the event of an untoward safety observation, the investigator may unblind a subjectâ€™s 
treatment assignment using the randomization and treatment supply management (RTSM). 
If possible, the investigator should first contact t he Theravance Clinical Study Director 
before unblinding. The blind should be broken only if knowledge of the subjectâ€™s study medication would affect subsequent treatment and such knowledge is required for the clinical management of the subject. Any investigator unblinding will be documented within the 
appropriate section of the subjectâ€™s case report from (CRF) and will be captured in the 
RTSM.  
Unblinding of individual study subjects or site staff on the basis of results from the study 
procedures (i.e., self -unblinding) is not considered to be either an expected or likely event.   

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 28 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  3.5.2. Treatment Assignment  
After a subject is screened and the investigator determines that the subject is eligible for 
enrollment, the subject will be randomized to one of the two treatment groups using RTSM  
(Day 1 visit  
 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 29 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  4. STUDY POPULATION  
The following inclusion and exclusion criteria must be satisfied before subjects are entered 
into the study: 
4.1. Inclusion Criteria 
1. Subject is a male or female subject 40 years of age or older (age at Visit 1A). 
2. Subject is willing and able to provide signed and dated written informed consent to participate at Visit 1A prior to initiation of any study related procedures.  
3. Subject is capable of performing reproducible spirometry maneuvers as described by 
current American Thoracic Society (ATS) Guidelines and has a post- ipratropium 
FEV
1/FVC ratio <0.7 at Visit 1B.  
4. Subject has moderate -to-very severe stable COPD with a post -ipratropium FEV 1 less 
than 80% of predicted normal at Visit 1B and a post-ipratropium FEV 1 >700 mL at 
Visit 1B. 
5. Subject has a current or past cigarette smoking history (or equivalent for cigar or pipe smoking history) of at least 10 pack- years. 
6. Subject must be willing and able to attend study visits according to the visit schedule  
and adhere to all study assessments/procedures . 
7. Female of either child bearing potential or non-child bearing potential as follows: 
â€¢ Female of childbearing potential must have documentation of a negative urine 
pregnancy test at Visit 1B and again at Visit 2 (prior to randomization) if Visit 2 
is > 7 days after Visit 1B . If a urine pregnancy test is positive, it must be 
confirmed via a second urine pregnancy test. All female subjects of childbearing 
potential must agree to use a highly effective method of birth control during the study and for at least 1 month after completion of study drug dosing.  
âˆ’ A highly effective method of birth control is defined as one that results in a 
low failure rate (i.e., <1% per year) when used consistently and correctly, such 
as condom + diaphragm, condom + spermicide, diaphragm + spermicide, or 
intrauterine device [IUD] with documented failure rate of <1% per year, or oral/injectable/implanted hormonal contraceptives used in combination with 
an additional barrier method.  
âˆ’ Females are considered to  be not of childbearing potential if they have had a 
total hysterectomy and/or bilateral tubal ligation (documentation for either 
must be provided before enrollment) or are at least 2 years postmenopausal 
(>24 months since last menstrual period).  
 
  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 30 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  4.2. Exclusion Criteria 
1. Females who are pregnant,  planning to become pregnant, or breastfeeding during the 
study. 
2. Subject has a significant respiratory disease or disorder other than COPD that, in the 
opinion of the investigator, would interfere with the interpretation of data from this study including, but not limited to, restrictive lung disorders, benign or malignant 
tumors of the lung, chronic pulmonary infections such as tuberculosis, occupational 
lung disease such as silicosis or asbestosis, inflammato ry disorders of the lung, 
alpha-1-antitrypsin deficiency, and/or abnormalities of the chest wall or musculature 
(e.g., scoliosis, myasthenia gravis, phrenic nerve palsy).  
3. Subject has a history of cancer of any organ, treated or untreated in the 5 years prior 
to Visit 1A (excludes localized basal cell or squamous cell carcinoma of the skin; 
localized prostate cancer in situ of grade 1; localized cervical cancer in situ of 
grade 0). 
4. Subject has a concurrent disease or condition that, in the opinion of the investigator, 
would interfere with study participation or confound the evaluation of safety, 
tolerability, or pharmacokinetics of the study drug. 
5. Subject has a history of reactions or hypersensitivity to inhaled or nebulized 
anticholinergics, short- acting beta-agonists and long- acting beta -agonists. 
6. Subject suffers from any medical condition that would preclude the use of inhaled 
anticholinergics, including narrow -angle glaucoma, symptomatic benign prostatic 
hyperplasia, bladder neck obstruction, or urinary retention. 
7. Subject has a significantly increased risk of cardiovascular events, as assessed by the investigator, and indicated by a history at Visit 1A of myocardial infarction or 
unstable angina within the last 6  months, new , unstable or life threatening  cardiac 
arrhythmia requiring intervention in the last 6 months, or New York Heart 
Association (NYHA) Class IV heart failure.  
8. Subjects with clinically significant and uncontrolled hypertension, 
hypercholesterolemia or Type II diabetes mellitus , as assesse d by the investigator . 
9. Subject has been hospitalized for COPD or pneumonia within 8 weeks prior to 
Visit 1B. 
10. Subject has used systemic corticosteroids within 8 weeks prior to Visit 1B. 
11. Subject has used antibiotics for respiratory tract infections within 8 weeks prior to Visit 1B. 
12. Subject is unwilling or unable to stop the use of prohibited medications during the 
washout (if required) and treatment period and follow-up period of the study. 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 31 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  5. STUDY DRUGS  
All study drugs supplied by the Sponsor must be stored in a secure location accessible only to 
designated study personnel. The assignment of subjects to one of the treatment groups will be 
accomplished by randomizing the subject through the RTSM. Each drug kit will contain a 
unique kit number which will be provided by the RTSM on Day 1 to identify the study drug kits to dispense to a particular subject.  
More information regarding study drug dispensing, administration, handling and storage are 
provided in a separate Pharmacy Manual.  
5.1. Description of Study Drugs  
5.1.1. Revefenacin and Placebo  
Revefenacin  has a molecular weight of  It is a  
 
 
 
  
Revefenacin and its placebo must be stored in a secure location accessible only to designated study personnel,   
Placebo inhalation solution is identical in appearance to the active  
  
Detailed instructions for administration will be provided in the Pharmacy Manual .  
5.1.2. Formoterol 
Formoterol will be provided in a carton containing 30 foil wrapped vials each contai ning 
2 mL of a solution of 20 mcg/2 mL formoterol fumarate for inhalation by nebulization.   
Formoterol should be stored in a secure location at room temperature (2Â°C to 25Â°C or 36Â°F 
to 77Â°F).    
Detailed instructions for administration will be provided in the Pharmacy Manual.  
5.2. Dosage and Administration  
5.2.1. Revefenacin  
Revefenacin will be admin istered immediately prior to administration of formoterol on the 
morning of Day 1 in the clinic. This will continue each day at home until Day 21.  On the 
morning of Day 21 the subject will not administer the dose at home since this dose will be 
administer ed at the clinic. The subject will take the jet nebulizer, compressor and study drug 
home where dosing will occur every morning at approximately the same time and will be 
within the window of 6 am and 11 am.  Revefenacin will be administered immediately be fore 
formoterol each day.  Formoterol will be also be administered in the evening. 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 32 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Training on the home use of the nebulizer will take place after the subject is randomized on 
Day 1 prior to discharge from the clinic. Subjects will be trained to administer  the study drug 
until nebulization of the study drug solution is complete, which takes approximately 10 minutes and is evidenced by â€œsplutteringâ€ of the nebulizer. Administration will be once daily in the morning at approximately the same time each day and  the time of administration 
will be recorded by the subject in their diary. This time will be chosen based on convenience for the subject and will remain the same for the duration of the study. The subject may receive additional instruction at the site bas ed on the judgment of the investigator. Additional 
information on the training of the subject on home nebulization is contained in the Pharmacy Manual. 
5.2.2. Formoterol 
Formoterol will be sequentially administered on the morning of Day 1 in the clinic, 
i.e., immediately after the administration of revefenacin.  This will continue each day at 
home until Day 21.  On the morning of Day 21 the subject will not administer the dose at home since this dose will be administered at the clinic.  Formoterol will also be administered 
approximately 12 hours after the morning dose each evening.  
At the end of the Day 21 visit, training will be provided to the subject on how to administer 
the revefenacin and formoterol as a combined solution, rather than sequentially, as a si ngle 
nebulization session.  The first dose of the combination of revefenacin and formoterol will not begin however until the next morning at home on Day 22 and continue until Day 41.  On the morning of Day 42 the subject will not administer the dose at hom e since this dose 
will be administered at the clinic.  
Formoterol will be administered every evening throughout the study from Day 1 until Day 41.  The time of the evening administration will be within the window of 6 pm and 
11 pm.   
The time of administration of the morning dose of revefenacin and formoterol (either 
sequentially or combined), and the evening dose of formoterol, will be recorded by the 
subject in their diary.  Refer to the package insert for further information. 
5.2.3. Agents for Rescue or Responsiveness Testing  
5.2.3.1. Ipratropium  
Ipratropium will be provided as a solution for administration via jet nebulizer for 
responsiveness testing during screening, at a dose of 500 mcg .  Refer to the package insert 
for further information.  
5.2.3.2. Albuterol  
All patients will be supplied with study- specific rescue medication (albuterol MDI) at 
Visit 1A for use throughout the remainder of the study.  Subjects will be advised to avoid use 
of their rescue medication for at least 6 hours prior to each visit.   
Subjects will return the albuterol MDI at each of the following study visits (Visit 2, Visit 3 
and Visit 4).  Additional albuterol will be dispensed as needed. 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 33 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  The subject will be allowed to retain their albuterol MDI at the end of the study for their own 
use. 
Refer to the package insert for further information. 
5.3. Treatment Compliance  
Compliance will be assessed in study subjects when accountability is performed as described 
in the next section. Compliance will be defined as subjects who are considered to have 
received 80 -120% of the total number of doses that should have been administered in 
between study visits.  
Compliance outside the 80-120% range will be documented in the e lectronic CRF (eCRF) as 
to reasons why, the number of doses that were outside this range, and whether any adverse 
event occurred as a result of the non -compliance.   
5.4. Drug Accountability and Reconciliation  
The investigator or designee is responsible for maintaining accountability records for all study drug(s) received from the Sponsor, in accordance with applic able government 
regulations and study procedures. The accountability record will include entries for receipt, distribution or dispensing, and the on- site destruction or return of the material(s) as specified 
by the sponsor. Unused and expired study drugs will be disposed of in accordance with 
written instructions from Sponsor. 
Study drug accountability will be performed at Visit 3 (Day 21), Visit 4 (Day 42) and any 
unscheduled visit or early termination visit where study drug is returned, to document 
compliance with the dosing regimen. Subjects will be instructed to bring back all remaining 
study drug and all study drug packaging at each study visit for drug accountability. 
Treatment compliance will be assessed by subtracting the number of unused returned foil 
pouches from number of foil pouches that were supplied to the subject (for revefenacin and 
formoterol).  I f a subject does not return the unused foil pouches, it will be assumed that the 
subject administer ed the study drug . If a subject misses recording  any dose of study drug 
based on the subjectâ€™s diary, the site personnel should discuss the missing entries to 
determine if the missing entries are due to not recording the administration in the diary and make any necessary corrections to the diary while the subject is on site. Discrepancies 
between the subjectâ€™s diary and the count of returned study drug should be documented in the 
source documents. 
Albuterol count will be not be captured for this study.  Subjects should return their albuterol 
inhaler(s) a t each study visit, and returns should be documented on the accountability logs.  
Subjects will be allowed to retain their albuterol MDI at the end of the study for their 
own use.   
 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 34 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  6. STUDY PROCEDURES  
6.1. Schedule of Study Procedures  
The schedule of study procedures is summarized in ( Table 1). 
Throughout the study, investigators should conduct the order of the assessments for each 
study visit as indicated in the study procedures and strive to maintain consistency in this 
order. All study procedures for a visit must be completed on the same day. Any missed visits, test not done, or procedures that are not conducted must be reported as such on the eCRFs.  
The scheduling of Visit 3 (Day 21 Â± 7  days) and Visit 4 (Day 42, Â± 7  days) is based on the 
date of occurrence of Visit  2 (Day 1 of the treatment period when the subject is randomized). 
The follow-up phone call should be scheduled 7 days after Visit 4, with a Â± 2 day visit 
window. 
6.2. Total Blood Volume  
The total volume of blood to be drawn from each subject for safety laboratory assessments 
(hemogram/hemoglobin and clinical chemistry) will be approximately 13.5 mL.  Additional 
samples may be necessary.  
6.3. Procedures by Visit 
Screening assessments and study procedures outlined in this section can only be performed 
after obtaining informed consent. Importantly, this includes any washout of a subjectâ€™s 
current medication for the purpose of participation in the study or chan ging a subjectâ€™s 
combination medication containing an inhaled steroid to inhaled steroid monotherapy 
  
Prior medical history should be obtained for the previous 2 years as part of screening the subject for eligibility into the trial.  If these records h ave not been obtained, then documented 
efforts to obtain these records must be present in the source documents. 
Participants in this study who, at the time of screening , are taking COPD medications 
requiring a washout will have two  screening visits (1A  and 1B).  
 
 
 
 
 
 
   
Subj
ects on LABAs (e.g., salmeterol, indacaterol, vilanterol, formoterol, arformoterol, 
olodaterol) must be prepared to stop these medications and switch to nebulized formoterol 
for the duration of the study. There is no washout period for LABAs, but the last dose of these medications should have been taken no sooner than 12 hours (for BID medications such 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 35 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  as salmeterol, formoterol or arformoterol) or 24 hours (for Q D medications such as vilaterol 
and indacaterol) before the randomization visit.  
Subjects on LABAs in combination with an ICS (e.g., fluticasone propionate, fluticasone 
fuorate, budesonide, ciclesonide, beclomethasone) will need to be switched to ICS monotherapy at the same or equivalent dose. Subjects must have been on a stable dose of ICS 
for at least 30 days prior to study entry. (A change from ICS/LABA to an equivalent ICS 
dose does not require this 30 day stability period). As with LABA monotherapy, if the subject is going to switch to an equivalent ICS monotherapy dose, this can occur on the day 
of randomization, assuming the last dose of LABA occurred as described above 
(12 or 24 hours prior to the visit as appropriate). 
Subjects on TRIPLE therapy would need to follow rules for washing out of the LAMA 
primarily, switching to a LABA and an ICS during this period of time, and then switching to 
study medication for the LABA on the day of randomization as described above. 
The first visit will be Screening Visit 1A.  Informed consent will be obtained and the 
subjectâ€™s existing COPD medication will be assessed to decide whether any adjustments are 
required to comply with the requirements of the protocol. If required, subjects will start a washout period only after signing the informed consent form. After completing the necessary 
washout period (if required) subjects will return for Screening Visit 1B within 7 days.  
If a washout period is not required then the first two screening visits (Visit 1A and Visit 1B) 
may be conducted as one visit.  The time period from Visit 1B (whether this is combined 
with Visit 1A or not) to randomization at Visit 2 will be 2 to 7 days.  Review of the 
spirometry at Visit 1B by the central spirometry vendor will take approximately 2 business days and must be completed to determine if the spir ometry meets the eligibility criteria 
before the subject can be randomized. 
If a subject does not meet the eligibility criteria for reasons of a failed screening test due to a 
properly administered procedure, this test or procedure will not be allowed to be repeated and 
the subject should be screen failed. This includes spirometry, i.e., if a subject fails to meet any spirometry related criteria after the first attempt the subject should be screen failed.  Repeat screening spirometry will only be considered  if there is a technical issue (e.g.,  with 
the spirometer or with the software) or if the spirometry was not performed properly due to site error.  
6.3.1. Visit 1A (Screening Visit) â€“ (performed up to 7 days before Visit 1B ) 
The following procedures will be performed at this visit:  
â€¢ Written informed consent after the nature of the study has been explained and 
before any study procedure is performed  
â€¢ Concomitant and previous relevant medication and medical history including an assessment of the subjectâ€™s COPD medicat ion 
â€¢ Review of inclusion and exclusion criteria 
â€¢ If required,  subject will begin 
their washout. If subject is receiving a combination COPD medication containing 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 36 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  an inhaled steroid this may include changing this medication to an inhaled steroid 
monother apy. 
â€¢ Subject will be dispensed one albuterol MDI as a rescue bronchodilator    
â€¢ Subject wi ll be trained on and dispensed the daily diaries   
6.3.2. Visit 1B â€“ (if a washout is not required Visit  1A and 1B may  be conducted as 
one visit) 
Subject should not have taken their LABA for approximately 12 hours (if on BID therapy) or 
approximately 24 hours (if on QD therapy) prior to the dose of ipratropium at this visit.  
Additionally, subjects should have refrained from taking their study supplied albuterol for 6 hours prior to spirometry assessments. They should further refrain from using albuterol 
throughout the study visit. 
â€¢ Predose of ipratropium 
âˆ’ Complete physical examination  
âˆ’ Height and weight 
âˆ’ Vital signs  (blood pressure or BP and HR) - subjects need to be resting in a 
semi-recumbent position approximately 5 minutes pri or to assessment of vital 
signs Perform  
âˆ’ ECG 
â€¢ Review of inclusion and exclusion criteria 
â€¢ A urine pregnancy test will be done for females of childbearing potential 
â€¢ Ipratropium Reversibility  - Spirometry reversibility testing pre - and postdose 
ipratropium  Spirometry 
will be performed predose and 45 minutes postdose (Â± 10 minutes) .  
â€¢ Concomitant Medications 
â€¢ Adverse Events  
â€¢ Collect and review Daily Diary (if diary was given at Visit 1a )  
â€¢ Subject will be trained on and dispensed the daily diaries  
 
6.3.3. Treatment and Follow- up Period  
6.3.3.1. Visit 2 (Randomization Visit)  
The time period from Visit 1B (whether this is combined with Visit 1A or not) to 
randomization at Visit 2 will be 2 to 7 days.  The following  procedures will be performed at 
Visit 2.  The timing of predose procedures is relative to the start  of study drug administration 
(start of nebulization of revefenacin). The timing of procedures postdose study drug administration is relative to the completion of nebulization of formoterol. 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 37 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  The sequence of events for the subject to follow at home will be as follows:  recording the 
start time of study drug (start of nebulization of revefenacin) in the paper diary, followed 
immediately by nebulization of formo terol).  
Subject should not have taken their LABA for approximately 12 hours (if on BID therapy) or 
approximately 24 hours (if on QD therapy) prior to taking it in the clinic. Additionally, 
subjects should have refrained from taking their short acting bronchodilators (study supplied 
albuterol) for 6 hours prior to ECG assessments. They should further refrain from using albuterol throughout the study visit. 
It is important at study visits that   The 
sequenc 
e of study medication will be:  nebulized revefenacin (or matching placebo) until the 
nebulizer sputters (emptying the nebulizer cup completely by tapping it on a clean dry 
surface until it is further emptied ), then nebulized formoterol until the nebulizer again  
sputters.  
The following procedures will be performed at the Randomization Visit: 
â€¢ Vital signs  
â€¢ Review of inclusion and exclusion criteria 
â€¢ Urine pregnancy test if visit is > 7 days after visit 1 B 
â€¢ Randomization (subject eligibility must be confirmed by  investigator before 
randomizing subject) 
â€¢ Dispense study drug ( RTSM will assign 1 kit of revefenacin or placebo (AM) and 
2 kits of formoterol (AM and PM)) 
â€¢ Concomitant medications  
â€¢ Adverse events  
â€¢ Dispense Rescue Medication and training on use 
â€¢ Collect and review Daily Diary and reconcile rescue medication as appropriate.   
â€¢ Dispense Daily Diary  and train on use 
â€¢ Hematology and serum chemistry lab draw 
â€¢ Perform predose ECG at 60 mins predose 
â€¢  
â€¢ St
udy drug dosing via nebulization of revefenacin/placebo followed immediately 
by nebulization of formoterol . Training on how to perform nebulization will be 
completed as part of these first doses, so that the subject can perform 
self-administration at home.  
â€¢ Perform ECG 10 mins postdose     
â€¢  

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 38 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  â€¢ Record Study Drug use and any in- clinic rescue medication use on daily diary 
and/or in source documents 
6.3.3.2. Visit 3 (Day 21 Â± 7  days) 
Subject should not have taken their albuterol for at least 6 hours prior to their ECG. They 
should further refrain from using albuterol throughout the study visit. 
It is important at study visits th at . 
The fol
lowing procedures will be performed at the Visit 3: 
â€¢ Physical Exam  
â€¢ Vital signs  
â€¢ Dispense study drug ( RTSM will assign 1 kit of revefenacin or placebo (AM) and 
2 kits of formoterol (AM and PM)) 
â€¢ Collect and reconcile returned study drug (with compliance assessment) and 
rescue medication  
â€¢ Dispense Daily Diary  and train on use 
â€¢ Concomitant medications  
â€¢ Adverse events  
â€¢ Dispense Rescue Medication and training on use 
â€¢ Hematology and serum chemistry lab draw 
â€¢ Perform predose ECG at 60 mins predose  
â€¢  
â€¢ St
udy drug dosing via nebulization of revefenacin/placebo followed immediately 
by nebulization of formoterol  
â€¢ Perform postdose ECG at 10 mins postdose 
â€¢  
â€¢ Rec
ord Study Drug use and any in- clinic rescue medication use  
â€¢ Before discharging the subject from clinic, they should be trained on how to 
self-administer a combined solution of revefenacin/placebo and formoterol in a 
single nebulization session.  (The first dose of the combined solution, however, will not be administered until the next morning after the subject has returned 
home).     

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 39 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  6.3.3.3. Visit 4 (Day 42 Â± 7  days) 
Subject should not have taken their albuterol for at least 6 hours prior to their ECG. They 
should further refrain from using albuterol throughout the study visit. 
It is important at study visits that  
The fol
lowing procedures will be performed at Visit 4: 
â€¢ Physical exam  
â€¢ Vital signs (BP and HR)  
â€¢ Urine pregnancy test  
â€¢ Collect and reconcile returned study drug (with compliance assessment) and 
rescue medication  
â€¢ Concomitant medications  
â€¢ Adverse events   
â€¢ Collect and Review Daily Diary  
â€¢ Hematology and serum chemistry lab draw 
â€¢ Perform predose ECG at 60 mins predose 
â€¢  
â€¢ St
udy drug do sing via nebulization of combined dose of revefenacin/placebo 
mixed with  formoterol   
â€¢ Perform postdose ECG at 10 mins postdose 
â€¢  
â€¢ Rec
ord Study Drug use and any in- clinic rescue medication us e 
6.3.3.4. Visit 5 (Telephone Follow-up) (7 Days Â± 2 days after Visit 4) 
The following reviews with the subject will take place via telephone.  
â€¢ Concomitant medications  
â€¢ Adverse events  
6.3.4. Early Termination  
The following procedures will be performed at the Early Termination/Withdrawal Visit  
â€¢ Physical exam  
â€¢ Vital signs ( BP and HR)  
â€¢ Urine pregnancy test  
â€¢ Collect and reconcile returned study drug  and assess compliance  

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 40 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  â€¢ Concomitant medications  
â€¢ Hematology and serum chemistry lab draw 
â€¢ Adverse events  
â€¢   
â€¢ Co
llect and review of Daily Diary  
â€¢ Collect and reconcile rescue medication   
In the instance of a subject terminating early due to an adverse event a telephone follow-up 
visit will be conducted 30 days afterwards  to review concomitant medications and advers e 
events. 
6.3.5. Unscheduled Visits  
Unscheduled visits may be performed at any time during the study whenever necessary to assess for or follow -up on adverse events, at the subjectâ€™s request, or as deemed necessary by 
the investigator. The date and reason for the unscheduled visit should be recorded in the source documentation. The following activities may be completed at unscheduled visits as required or medically indicated:  
â€¢ Medical history update 
â€¢ Vital Signs  
â€¢ Physical Exam  
â€¢ Dispense replacement study drug or rescu e albuterol 
â€¢ Record concomitant medications  
â€¢ Record adverse events  
â€¢  
â€¢ ECG 
â€¢ H 
ematology and serum chemistry lab draw 
6.4. Description of Study Assessments  
6.4.1. Demographic and Baseline Assessments  
After obtaining informed consent, each subject will be asked to provide a relevant medical history including medication history, concomitant medications, and demographic information 
including date of birth, sex, race, and ethnicity .  The subject will also undergo a physical 
examination including vital signs, height, and weight and also will have the following 
assessments measured;   and 
a uri 
ne pregnancy test for females  of child-bearing potential. 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 41 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  6.4.2. Assessments  
6.4.3. Safety Assessments 
6.4.3.1. Adverse Events  
Adverse events will be reviewed and recorded from the signing of the informed consent 
through the last day  of the follow-up visit. Adverse events may be observed by the site study 
personnel or spontaneously reported by the subject. Subjects will be reminded to call the site 
to report AEs that occur between visits. 
6.4.3.2. Medical History  
Complete medical history at screening will include evaluation for past and present 
cardiovascular, respiratory, gastrointestinal, renal, hepatic, neurological, endocrine, 
lymphatic , hematologic, immunologic, dermatologic, psychiatric, genitourinary, substance 
abuse, surgical history , or any other diseases or disorders. 
6.4.3.3. Physical Examination 
Physical examinations will include examination of the following: general appearance; head, ears, eyes, nose, and throat; neck, cardiovascular system, respiratory system, abdominal 
system, lymphatic system, dermatologic system, musculoskeletal system, and nervous 
system.  
6.4.3.4. Vital Signs  
Blood pressure (BP), and heart rate ( HR), will be recorded  only once in the eCRF for each 
protocol specified time point ; at screening only, a second  measurement  may be obtained to 
rule out sustained elevation/decrease of either systolic or diastolic blood pressure. Subject need to be resting in a semi- recumbent position for approximately 5 minutes prior to 
assessment of vital signs.  BP will be measured manually using a mercury 
sphygmomanometer or calibrated automatic blood pressure device. HR will be measured by palpation of the radial pulse over a 60-second period or by the automated blood pressure device.  
6.4.3.5. Laboratory Tests 
A central lab will be used for all laboratory assessments. Specimen collection times are 
specified in the Schedule of Study Procedures and all assessments will be performed non-fasting.  
6.4.3.5.1. Hematology 
Hematocrit and hemoglobin , red blood cell count; white blood cell count, including 
differential count of total neutrophils, eosinophils, basophils, monocytes, lymphocytes; mean corpuscular volume; mean corpuscular hemoglobin; and mean corpuscular hemoglobin 
concentration; and platelet count.  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 42 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  6.4.3.5.2. Serum Chemistry  
Sodium, potassium, chloride, bicarbonate (if available), blood urea nitrogen ( BUN), 
creatinine, magnesium, calcium, phosphate, total bilirubin , direct and indirect bilirubin, 
alkaline phosphatase, lactate dehydrogenase, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyl transferase , and glomerular filtration rate ( GFR) 
(derived from serum creatinine).  
6.4.3.6. ECG â€“ 12-lead  
ECGs will be done singly following a 5- minute semi-recumbent  rest at: 
â€¢ Screening Visit 1B  
â€¢ Visit 2 (Randomization Visit):  1 hour pre-dose, and 10 minutes post-dose. 
â€¢ Visit 3 (Day 21) and Visit 4 (Day 42):  1 hour pre-dose and 10 minutes post-dose.  
The time window for the 1 hour pre-dose spirometry will be Â± 10 minutes.  The time window 
for the 10 minutes post- dose spirometry will be + 10 minutes only (with no â€“ window). 
6.4.3.7. Pregnancy  
Urine pregnancy tests will be performed in women of child bearing potential. A positive 
urine pregnancy test will be confirmed with a second urine test. If the subject is an early termination or withdrawal, a urine pregnancy test will also be performed at the early termination visit.  
  
 
 
  
   
 
 
 
 
  
6.5. Concomitant Medications  
Inhaled maintenance steroid therapy will be continued at the allowed maintenance dose 
throughout the treatment and washout periods. Albuterol will be allowed as required 
(or â€œPRNâ€) during the study. Albuterol should be withheld for at least 6 hours before the 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 43 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  ECG   
Only study supplied albuterol should be used during the subjectâ€™s participation in the study. 
If subjects have used albuterol within 6 hours of the ECG at the Visit 2, the visit should be 
rescheduled.  At each of the remaining visits, if this occurs, the visit will still be conducted, however this will be considered a protocol deviation. 
Subjects who are receiving a LABA or LABA/ICS (either QD or BID) may be enrolled into 
the study provided that the dose has been stable for at least 30 days prior to Screening and the steroid component is â‰¤1000 mcg /day equivalent to fluticasone propionate.  
Subjects on LABAs (e.g., salmeterol, indacaterol, vilanterol, formoterol, arformoterol, olodaterol) must be prepared to stop these medications and switch to nebulized formoterol for the duration of the study. There is no washout period for LABAs, but the last dose of 
these medications should have been taken no sooner than 12 hours (for BID medications such 
as salmeterol, formoterol or arformoterol) or 24 hours (for QD medications such as vilaterol 
and indacaterol) before the randomization visit. 
Subjects on LABAs in combination with an ICS (e.g., fluticasone propionate, fluticasone 
fuorate, budesonide, ciclesonide, beclomethasone) will need to be switched to ICS 
monotherapy at the same or equivalent dose. Subjects must have been on a stable dose of ICS 
for at least 30 days prior to study entry. (A change from ICS/LABA to an equivale nt ICS 
dose does not require this 30 day stability period). As with LABA monotherapy, if the 
subject is going to switch to an equivalent ICS monotherapy dose, this can occur on the day 
of randomization, assuming the last dose of LABA occurred as described above (12 or 
24 hours prior to the visit as appropriate). 
The triple therapy will need to be switched to a LABA and ICS therapy during the 48 hour 
washout of the LAMA component.  Then on Day 1 the subject will be switched again to 
receive an equivalent ICS monotherapy as the study treatment administration will be  in place 
of their LABA.  The ICS monotherapy should be continued for the duration of the treatment 
period.   
LABA and LABA/ICS drugs include the following examples:   
â€¢ fluticasone propionate/salmeterol combination product  
â€¢ budesonide/formoterol fumarate dihydrate combination product  
â€¢ fluticasone furoate/vilanterol combination product 
â€¢ mometasone /formoterol  
The initiation of new treatment for COPD during this study is strictly prohibited. If the 
subject experiences worsening of symptoms that requires additional therapy other than 
increased use of study supplied albuterol (i.e., an exacerbation of their COPD) they should be 
withdrawn from the study and, if the event qualifies, report this event as a serious adverse 
event.  
 
Subjects will be permitted to 
restart their routine medications after the completion of Visit 4.  

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 44 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.    
  
  
  
  
 
 
 
 
   
  
  
  
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 45 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.    
  
  
  
  
 
 
 
 
 
 
  
  
  
 
 
 
  
 
 
  
   
 
  
  
  
 
 
 
 
 
 
   
 
  

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 46 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.6. Restrictions 
Subjects are to observe the following requirements  from Screening through  to Day 42: 
â€¢ No use of recreational drugs 
â€¢ No use of medicinal marijuana 
â€¢ No use of excessive alcohol during the s tudy period 
â€¢ No participation in another investigational drug study 
â€¢ No donation of â‰¥500 mL blood (or equivalent) 
During study visits (i.e.,  when the subject is in clinic), smoking, exercise, or caffeine intake 
or large meals should be restricted  (further details provided in the 0167 Study Manual). 
6.7. Discontinuation  
6.7.1. Subject Discontinuation 
Any subject (or his or her legally authorized representative) may withdraw their consent to 
participate in the study at any time without prejudice . The investigator must withdraw from 
the study any subject who requests to be withdrawn or who meets any of the following 
criteria: 
â€¢ Subjects who experience a COPD exacerbation that is considered severe or results 
in a serious adverse event  
â€¢ Subjects who discontinue study drug for more than 7 days, regardless of the reason 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 47 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  A subjectâ€™s participation in the study may be discontinued at any time at the discretion of the 
investigator and in accordance with his or her clinical judgment. When possible, the tests and 
evaluations listed for the termination visit should be carried out. If a subject withdraws 
before completing the study, the reason for withdrawal is to be documented on the CRF. 
The Sponsor will be notified of all subject withdrawals.  
Reasons for which the investigator or the Sponsor may withdraw a subject from the study or 
a subject may choose to terminate participation before completion of the study include, but are not limited to, the following:  
â€¢ Adverse event  
â€¢ Subjectâ€™s choice 
â€¢ Major violation of the protocol 
â€¢ Termination of the study by the Sponsor 
â€¢ Other (e.g., subject personal circumstances)  
  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 48 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Table 3: Severity Criteria for COPD Exacerbations  
COPD exacerbation is defined as a complex of respiratory symptoms (increase or new onset) 
of more than one of the following: cough, sputum, wheezing, dyspnea, or chest tightness with 
a duration of at least 3 days requiring t reatment with SABAs, antibiotics, systemic steroids, 
or hospitalization. 
 
Severity of COPD exacerbation  Criteria  
Mild  A deterioration of COPD symptoms, in the judgment of 
the investigator, managed with an increased use of 
SABA but not requiring the use of antibiotics or oral or 
systemic corticosteroids.  
Moderate  A deterioration of COPD symptoms, in the judgment of 
the investigator, based on any one of the following criteria:  
â€¢ An acute change in symptoms with purulent sputum requiring treatment with a cours e of 
antibiotics for lower airway disease  
â€¢ An acute change in symptoms requiring 
treatment with a course of oral steroid for lower airway disease 
â€¢ Subjects meeting the above criteria may receive treatment in a hospital setting as long as the 
duration of the visit is <1 day  
Severe  A deterioration of COPD symptoms that results in 
hospitalization for emergency treatment of the COPD 
and the duration of the visit is â‰¥1 day.  
Subjects who experience a mild or moderate COPD exacerbation (one or more) may continue 
in the trial.  However, COPD exacerbations that are severe or result in a serious adverse event, will be discontinued from the trial.   
The Sponsor will be notified of all subject withdrawals.  
Subjects who discontinue study drug early because of an adverse reaction should be 
encouraged to continue their participation in the follow- up safety assessments . If a subject 
fails to return for scheduled visits, a documented effort must be made to determine the reason. 
6.7.2. Subject Replacement  
 
 
  

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 49 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  6.7.3. Study Discontinuation  
The Sponsor reserves the right to discontinue this study at any time for any reason.  
Certain circumstances may require the premature termination of the study , if the principal  
investigator and the Sponsor feel that the type, number and/or severity of AEs justify 
discontinuation of the trial, as for example, when  several cases of similar serious adverse 
events (SAEs) considered related by both the investigator and the Sponsor occur s. The 
Sponsor reserves the right to discontinue this study at any time for any reason.   
6.8. Pregnancy  
If a female subject becomes pregnant during the study, the clinical study director (or designee) must be notified immediately  and the subject discontinued from the study.  
The Investigator must report this to the Sponsor using the Pregnancy Reporting Form 
within 24 hours of becoming aware of the pregnancy. 
If not all information requested on the Pregnancy Reporting Form is available at the time 
of the initial report, follow -up reports must be completed and submitted within 24 hours of 
the Investigatorâ€™s becoming aware of any new information. The Investigator is required to follow up on the pregnancy until it has completed.  
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the infant will be required. The outcome of the pregnancy and the status of the newborn (if applicable) will be reported on the Pregnancy Reporting Form within 24 hours of the 
Investigatorâ€™s becoming aware of that information. 
6.9. COPD Exacerbations 
Exacerbations of COPD that are considered severe or result in a serious adverse event are cause for withdrawal from the study and will be capture d as a reason for study termination.  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 50 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  7. ADVERSE EVENTS  
7.1. Definitions 
The definitions below are based on International Conference on Harmonization (ICH) 
guideline E2A, â€œClinical Safety Data Management: Definitions and Standards for Expedited Reportingâ€. 
7.1.1. Adverse Events (AE) for the Purposes of This Study  
An AE is any untoward medical occurrence in a patient or clinical trial subject administered 
a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not related to the medicinal product.  
â€¢ AEs may be new events  
â€¢ Preexisting e vents that increase in frequency, severity or change in nature or 
seriousness during or as a consequence of participation in clinical studies. 
â€¢ Pre- or post-treatment complications that occur as a result of a protocol-mandated 
procedure (such as a biopsy). 
â€¢ AEs may be clinically significant changes from baseline in physical examination, laboratory tests, or other diagnostic investigation (e.g., laboratory results, x- ray 
findings). 
â€¢ AEs may result from an overdose of the study medication.  
Whenever possible, the diagnosis (rather than a series of terms related to a diagnosis) should be recorded as the AE term.  
An AE does not include the following: 
â€¢ All COPD exacerbations (mild, moderate and severe) will be qualified as an 
Adverse Event. Please see definitions of COPD exacerbations in Table 3. 
â€¢ Medical or surgical procedures (such as surgery, endoscopy, tooth extraction, or transfusion); the condition that leads to the procedure is an adverse event 
â€¢ Preexisting diseases or conditions present or detected before signing an informed consent form that do not worsen 
â€¢ Situations where an untoward medical occurrence has not occurred (such as hospitalization for elective surgery or social and/or convenience admissions) 
â€¢ Overdose of either study drug or concomitant medication without any signs or 
symptoms, unless the subject is hospitalized for observation 
Any medical condition or clinically significant laboratory abnormality with an onset date prior to the time the subject signed the informed c onsent form is considered to be preexisting 
and should be documented in the medical history CRF. 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 51 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Pregnancy is not an AE; however, if a female subject becomes pregnant during the conduct 
of the study, Theravance Biopharma will be notified according to the procedures for SAE 
reporting as outlined in Section  7.4.3.  Follow-up information regarding the outcome of the 
pregnancy and any fetal or neonatal sequelae will be obtained and documented. 
7.1.2. Serious Adverse Event (SAE)  
An SAE is defined as any untoward medical occurrence occurring at any dose that results in 
any of the following outcomes: 
â€¢ Death 
â€¢ Life-threatening situation.   â€œLife -threateningâ€ refers to a situation in which the 
patient was at risk of death at the time of the event; it does not refer to an event 
which might have caused death if it were more severe.  
â€¢ Inpatient hospitalization or prolongation of existing hospitalization  
â€¢ Note:  â€œInpatient hospi talizationâ€ means the subject has been formally admitted to 
a hospital for medical reasons, for any length of time. This may or may not be overnight. It does not include presentation and care within an emergency 
department. A scheduled hospitalization for a pre-existing condition that has not 
worsened during participation in the study does not meet this criterion. Pre-planned hospitalizations for an elective medical/surgical procedure, scheduled 
treatments, or routine check-ups do not meet this criterion. C omplications that 
occur during hospitalizations are AEs. If a complication prolongs hospitalization, it is an SAE.  
â€¢ Congenital anomaly/birth defect in the offspring of a subject who received study 
drug 
â€¢ Important medical events that may not result in death, be immediately life-threatening, or require hospitalization, may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and 
may require medical or surgical intervention to prevent one of the outcomes listed 
in this definition. Examples of such events are as follows: 
âˆ’ Intensive treatment in an emergency room or at home for allergic 
bronchospasm 
âˆ’ Blood dyscrasias or convulsions that do not result in hospitalization 
âˆ’ Development of drug dependency or drug abuse 
7.1.3. Additional Considerations for Serious Adverse Events  
â€¢ Death is an outcome of an adverse event and not an adverse event in itself. Deaths of unknown cause for which the investigator cannot identify a cause of death will 
be captured as death of unknown cause or death not otherwise specified. 
â€¢ All deaths, regardless of cause, must be reported for subjects if the death occurs 
while the subject is participating in the study.  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 52 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  â€¢ â€œOccurring at any doseâ€ does not imply that the subject is receiving study drug at 
the time of th e event; dosing may have been given as treatment cycles or 
interrupted temporarily before the onset of the SAE, but may have contributed to 
the event.  
7.2. Clinical Laboratory Abnormalities and Other Abnormal 
Assessments as Adverse Events or Serious Adverse Eve nts 
Abnormal laboratory findings (such as clinical chemistry  or hematology) or other abnormal 
assessments (such as ECGs, X -rays, or vital signs) that are considered clinically significant in 
the judgment of the investigator must be recorded as AEs or SAEs if they meet the definition 
of an adverse event (or serious adverse event), as described in Sections  7.1.1 (Adverse Event) 
and 7.1.2 (Serious Adverse Event). 
If there are any AE questions, t he investigator is encouraged to contact the Sponsor to 
discuss. 
7.3. Assessment of Adverse Events  
All AEs will be assessed by the investigator and recorded in the case report form, including 
the dates of onset and resolution, severity, relationship to study drug, outcome, and action taken with study medication. 
7.3.1. Severity 
The term â€œsevereâ€ is often used to describe the intensity (severity) of a specific event (as in 
mild, moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe nausea).  This is not the same as 
â€œserious,â€ which is based on patient/event outcome or action criteria usually associated with 
events that pose a threat to a subjectâ€™s life or functioning.  The severity of AEs will be assessed according to the following definitions:   
â€¢ Mild:  the AE is noticeable to the patient and/or the Investigator, but does not 
interfere with routine activity.  
â€¢ Moderate:  the AE interferes with routine activity, but responds to symptomatic 
therapy or rest.  
â€¢ Severe:  the AE significantly limits the patientâ€™s ability to perform routine activities despite symptomatic therapy.  
7.3.2. Causal Relationship to Study Medication 
The Investigatorâ€™s assessment of causality is based on clinical judgment regarding t he 
reasonable possibility that the study medication caused the event and may include 
consideration of some or all of the following factors: 
â€¢ Possible alternative causes of the AE, including the disease under treatment, 
co-morbid conditions, other drugs, and environmental factors. 
â€¢ The temporal  association between drug exposure and onset of the AE.  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 53 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  â€¢ Whether the clinical or laboratory manifestations of the AE are consistent with 
known actions or toxicity of the study medication. 
â€¢ Whether the AE resolved or improved with decreasing the dose or stopping the 
study medication (â€œdechallengeâ€) or recurred or worsened upon re-exposure to the 
study medication (â€œrechallengeâ€).  
The causal relationship between the study medication and the AE will be described using one of the following categories: 
â€¢ Not Related:   Evidence exists that the adverse event has an etiology other than 
the study drug (such as a preexisting condition, underlying disease, intercurrent illness, or concomitant medication).  
â€¢ Related: A temporal relationship exists between the event onset and 
administration of the study drug. It cannot be readily explained by the subjectâ€™s clinical state or concomitant therapies and appears with some degree of certainty to be related based on the known therapeutic and pharma cologic actions of the 
drug. In case of cessation or reduction of the dose, the event abates or resolves and reappears upon rechallenge. It should be emphasized that ineffective treatment should not be considered as causally related in the context of adver se 
event reporting. 
7.4. AE Reporting and Recording  
7.4.1. AE Reporting  
Timely, accurate, and complete reporting and analysis of safety information from clinical trials is crucial for the protection of patients and is mandated by regulatory agencies.  
Sponsor has established standard operating procedures in compliance with regulatory 
requirements worldwide to ensure appropriate reporting of safety information.  All clinical trials sponsored by TBPH will be conducted in accordance with these procedures.  
7.4.2. AE and SAE  Recording 
All AEs, regardless of seriousness, severity, or causal relationship to study medication, will 
be recorded from signing informed consent through the last study visit (or last subject contact in the case of a follow -up telephone call) .  AEs will be recorded on the AE page of the CRF.  
SAEs, regardless  of relationship to study medication will be recorded from signing informed 
consent through the last study visit (or last subject contact in the case of a follow -up 
telephone call).   Additionally, inves tigators may report SAEs assessed as related to study 
medication through 30 days following the last study visit (or last subject contact in the case 
of a follow-up telephone call). All SAEs will be recorded on both the SAE Report Form and the AE page of th e CRF and should include the following:   
  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 54 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Description of event :   
â€¢ Signs and symptoms due to a common etiology should be reported as a single 
diagnosis; for example, cough, runny nose, sneezing, sore throat, and head 
congestion would be reported as â€œupper respiratory infectionâ€.   
â€¢ A diagnosis or description must be as specific and as complete as possible 
(e.g., â€œlower extremity edemaâ€ instead of â€œedemaâ€).  
â€¢ Hospitalization or surgical procedures should not be used as adverse event terms (e.g., if a subject was hospitalized for cholecystectomy due to cholecystitis, the 
adverse event term should be recorded as cholecystitis, and not as the procedure, cholecystectomy).   
â€¢ â€œDeathâ€ should not be used as an adverse event term unless the cause of death is 
unknown.  For events with a fatal outcome, the cause of death should be the 
adverse event term  (e.g., if a subject died of an acute myocardial infarction, the adverse event term should be recorded as â€œMyocardial Infarctionâ€ and the event 
outcome as fatal).     
âˆ’ Relationship to study medication : The Investigator will make an assessment of 
the causal relationship of the study medication to the AE using the guidelines 
in Section  7.3.2.  
âˆ’ Severity: The severity of the AE will be assessed using the guidelines in 
Section 7.3.1. 
âˆ’ Outcome:  The outcome of AEs will be recorded.   
âˆ’ Therapeutic measures:  Measures taken for the treatment or management of 
the AEs will be recorded.  
7.4.3. SAE Reporting  Timeline  
SAEs will be reported to Clinical Safety and Pharmacovigilance within 24 hours of the time the Investigator or his/he r designee becomes aware that an SAE has occurred, whether or not 
the event is considered to be related to study medication.  If the initial SAE is reported by 
telephone, a written report signed by the Investigator must be submitted within 24 hours.   
The SAE Report Form must be completed in accordance with the SAE Report Form 
Completion Guidelines.  If all information on the SAE Report Form is not available at the 
time of the initial report, follow -up SAE reports will be completed and submitted.   
To report an SAE, complete and email or fax the Serious Adverse Event Report Form to the 
following: 
Theravance Clinical Safety and Pharmacovigilance (CSPV):  
Email:  
  
 
  

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 55 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  For medical questions regarding an SAE, contact the Sponsor medical monitor by telephone 
as follows: 
Sponsor Medical Monitor Contact Information:  
  
 
Telephone:  
Email:  
For fatal or life -threatening events, fax copies of hospital case reports, autopsy reports, and 
other documents when requested. Additional information may be requested from the investigator to ensure the timely completion of accurate safety reports.  
An SAE may qualify for reporting to regulatory authorities if the SAE is possibly attributable to the study drug and is unexpected/unlisted based on the current revefenacin  IB. In this case, 
all investigators will receive notification of the event. The inv estigator is responsible for 
notifying the Institutional Review Board or Ethics Committee and documenting the notification, as required by local regulatory authorities and in accordance with the local institutional policy.  
7.5. Adverse Event Follow -up 
A subject  experiencing an AE or SAE will be followed by the investigator or his/her trained 
delegate(s) through the follow-up visit or until the investigator and/or the Sponsor has determined that the AE or SAE has resolved or a stable clinical endpoint is reached,  
whichever is longer. The Sponsor may request follow-up of certain adverse events until resolution and documentation of assessments made during this period. 
The investigator must take all therapeutic measures necessary for resolution of an SAE. 
Any medications necessary for treatment of the SAE must be recorded in the concomitant 
medication section of the case report form. 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 56 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  8. STATISTICAL CONSIDERATIONS   
8.1. General Considerations  
All individual data will be listed as measured.  All statistical summaries and analyses will be 
performed using SAS software (SAS Institute, Cary, North Carolina, USA).   
Continuous data will be summarized using
 
   
Categorical data will be summarized using the frequency  
 
Any changes to the protocol- specified analyses will be pre- specified in the Statistical 
Analysis Plan prior to data lock. 
8.2. Sample Size and Power  
 
 
 
 
 
 
8.3. Analysis Sets 
The Safety analysis set will include all randomized subjects receiving at least one dose of 
study drug summarized by actual drug received. These subjects will be analyzed according to 
their actual treatment received, regardless of their randomized treatment. The Safety analysis 
set will be the primary analysis for safety analyses.  
The Intent -to-Treat (ITT) analysis set will include all randomized subjects.  Subjects in this 
set will be analyzed according to their randomized treatment assignments, regardless of treatment received.   
A per-protocol (PP) analysis will also be implemented and be considered supportive to the 
ITT analysis. The PP analysis set included all subjects in the ITT analysis set who did not violate the key inclusion/exclusion criteria through Day 42. S ubjects who received the 
incorrect treatment (compared to their randomized treatment) at any time point will be 
excluded from this subset. For subjects who received proscribed medications during the 
42-days treatment period, all data collected after the first occurrence of receiving proscribed 
medication will be excluded from the PP analys is. The key inclusion/exclusion criteria 
pertaining to the PP analysis and the list of proscribed medications will be included in the statistical analysis plan (SAP).   

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 57 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  8.3.1. Examination of Subgroups 
The following subgroups are pre- defined at baseline:  
â€¢ Baseline smoking status  
â€¢ Age  
â€¢ Current ICS use  
â€¢ Reversibility to (not reversible) to ipratropium,   
â€¢ Sex   
Selected analyses as defined in the SAP will be conducted using the subgroup examination 
sets. Additional subgroups may be defined in the SAP. 
8.3.2. Major Protocol Analysis Deviations 
The following protocol deviations are defined as major and would be considered to have an 
impact on the analysis of data.  
 
 
 
Additional criteria may be specified in the SAP.  
8.4. General Analys es 
8.4.1. Demographics Characteristics  
Demographics and baseline characteristics (including age, sex, race, ethnicity, height, weight, 
and body mass index [ BMI]) will be summarized for the ITT analysis set.  
8.4.2. Screening Summaries  
A summary of pulmonary function at screening, including reversibility, and at baseline using the ITT analysis set will be provided. 
8.4.3. COPD Clinical History and Smoking History  
A summary of the COPD clinical characteristics/history and smoking history using the ITT 
analysis set will be provided. 
8.4.4. Select Medical History  
A summary of select medical history/characteristics using the Safety analysis set will be 
provided characterizing co-morbidities and disease severity. 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 58 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  8.5. Safety Analyses  
For all safety analyses, the safety analysis population will be used. 
Safety variables to be summarized include vital signs, adverse events, clinical laboratory 
results (hematology  and chemistry), and corrected QT interval (QTcF) from standard safety 
digital ECGs. Vital signs will be summarized in terms of observed va lues and changes from 
baseline. 
8.5.1. Extent of Exposure 
A subjectâ€™s data for the extent of exposure to study drug will be generated from the study 
drug administration page of the CRF.  Dosing information for individual subjects will be listed.  Using drug administration data, estimates of exposure to revefenacin and /or 
formoterol  will be summarized.  Dose discontinuations and reasons for study drug 
discontinuation will be listed and summarized. 
8.5.2. Adverse Event Data  
Adverse events will be coded to the preferred ter ms of the Medical Dictionary for Regulatory 
Activities (MedDRAÂ®). Summaries will present by system organ class (SOC), preferred 
term (PT) and severity, the frequency and percentage of subjects reporting each observed event. 
Adverse events observed during the period from obtaining informed consent to the start of administration of study drug will be regarded separately from adverse events observed after 
study drug administration (i.e., treatment- emergent adverse events [ TEAEs]). 
A TEAE will be defined as any  AE that begins on or after the date of first dose of study drug 
up to the date of last dose of study drug plus the number of days in the follow-up period.  AEs observed during the period from obtaining informed consent to the start of 
administration of study drug will be regarded separately from TEAEs. 
All AEs and all TEAEs will be listed by subject.  The frequency of subjects who experience 
TEAEs will be summarized overall and by treatment group.  AE s will also be summarized by 
relationship to treatment (study drug) and severity. 
A listing will be provided for all subjects who experience an SAE.  Data listings will also be 
provided for subjects who discontinued the study due to any AE , as well as for a SAE.  
8.5.3. Concomitant Medications  
Medications will be summarized both prior and during the treatment period. Medications will 
be summarized in the following classes, COPD bronchodilator, ICS and non- COPD 
medications . 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 59 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  8.5.4. Laboratory Data 
Laboratory data will be summarized in terms of observed values, changes from baseline, 
values relative to normal ranges, and changes from baseline relative to normal ranges. 
Listings will flag laboratory values that are outside of normal range.  
Clinical laboratory test results will be listed by subject.  Reference ranges provided by  the 
laboratory for each parameter will be used to evaluate the clinical significance of laboratory test results .  Values falling outside of the relevant reference range will be flagged, as 
appropriate, in the data listings.   Abnormalities in clinical laboratory test results will be listed 
in a separate listing .   
8.5.5. Vital Signs Data 
Vital Signs  data will be summariz ed in terms of observed values (by time point), changes 
from baseline (by time point), and counts and percentages within appropriately defined 
categories (Table 4). 
Table 4: Outlier Threshold for Vital Signs  
Heart Rate 
(bpm) Systolic Blood Pressure  
(mmHg) Diastolic Blood Pressure (mmHg) 
<40 
>110 <85 
>160 <45 
>100 
8.5.6. ECG Data  
The QTcF, PR interval, QT interval, QRS duration, and HR from standard digital ECGs will 
be summarized in terms of observed values, changes from baseline, and counts and 
percentages within appropriately  defined categories ( Table 5). 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 60 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Table 5: ECG Test Outlier Thresholds   
Heart 
Rate 
(bpm) Heart Rate 
Change from 
Baseline (bpm)  PR 
 Interval 
(msec) PR Percentage 
Change From 
Baseline (%)  QRS 
 Interval 
 (msec) QTcF 
(msec) QTcF change 
from Baseline (msec) 
>120 â‰¥20 â‰¥ 200 â‰¥ 15 â‰¥ 120 Males: â‰¤ 30 
>130 â‰¥30 â‰¥ 220 â‰¥ 25  < 430 >30, â‰¤ 60  
  Optional:    â‰¥ 430 > 60 
  â‰¥ 240   â‰¥ 450  
  â‰¥ 260   â‰¥ 470  
  â‰¥ 280   â‰¥ 480  
  â‰¥ 300   â‰¥ 500  
     Females:  
     < 450  
     â‰¥ 450  
     â‰¥ 470  
     â‰¥ 480  
     â‰¥ 500  
Treatment emergent ECG abnormalities are defined as those not present at baseline, or those 
that worsened after treatment, e.g., borderline at baseline, but were prolonged after treatment. 
QTcF {and QTcB} will also be summarized by the following categories, Normal (males <430, females <450), Borderline (males (â‰¥430, <450); females (â‰¥450, <470)) and Prolonged 
(males â‰¥450, females â‰¥470). 
When multiple values exist for the same nominal time point (e.g. , triplicate reading), the 
average of the readings taken for ECG parameters wi ll be used in the data analysis, including 
the outlier analysis stated below.  
There will be no imputation of missing data. Subjects without post- baseline measurement for 
a given treatment period will be excluded from the summary statistic  (e.g., denominator of 
the summary statistic)  for that time point.   
All recorded values for the ECG parameters will be presented in a by -subject listing.  
A separate listing of subjects with values of QTcF > 500 msec or an increase > 60 msec will 
be provided, as necessary . 
Cumulative distribution plots will be provided for maximum change in QTcF by day. 
8.6. Other Analyses 
For other analyses, the ITT population will be used. In select analyses, the PP and subgroup examination sets may be used.  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 61 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  8.6.1. Other Endpoints  
 
  
  
   
  
 
 
 
 
   
 
 
 
 
 
 
  
 
 
 
 
 
   
 
   
  
 

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 62 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.    
 
 
8.6.5. Mu
ltiplicity Adjustment  
  
 
8.7. Missing Data Handling  
 
 
 
 
8.8. Data Monitoring Committee  
No data monitoring committee is planned for this study.  

Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 63 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  9. STUDY ADMINISTRATION 
This study will be conducted in compliance with all applicable regulations.  
9.1. Principal Investigator Responsibilities  
Before beginning the study, the principal investigator (PI) at each site must provide to the 
Sponsor or its designee a fully executed and signed Form FDA 1572 and, if applicable, a 
financial disclosure form. For applicable studies, financial disclosure for ms must also be 
completed for all subinvestigators who will be directly involved in the treatment or 
evaluation of research subjects in this study. (A subinvestigator is defined in ICH E6 as any 
individual member of the clinical study team designated and supervised by the investigator at 
a study site to perform critical study -related procedures and/or to make important 
study-related decisions [e.g., associates, residents, research fellows].)  
The PI will ensure the following: 
â€¢ He or she will conduct the study in accordance with the relevant, current protocol 
and will only make changes in a protocol after notifying the sponsor, except when 
necessary to protect the safety, rights, or welfare of subjects.  
â€¢ He or she will personally conduct or supervise the study. 
â€¢ He or she will inform any potential subjects, or any persons used as controls, that 
the drugs are being used for investigational purposes and he or she will ensure that the requirements relating to obtaining informed consent in 21 CFR  Part 50 
and institutional review board (IRB) review and approval in 21 CFR  Part 56 are 
met.  
â€¢ He or she will report to the sponsor adverse experiences that occur in the course 
of the investigation in accordance with 21 CFR  312.64. 
â€¢ He or she has read and understands the information in the Revefenacin  IB, 
including potential risks and side effects of the drug. 
â€¢ His or her staff and all persons who assist in the conduct of the study are informed 
about their obligations in meeting the above commitments  
â€¢ He or she will ensure that adequate and accurate records in accordance with 21 CFR 312.62 and to make those records available for inspection in accordance 
with 21 CFR  312.68. 
â€¢ He or she will ensure that the IRB/ independent ethics committee ( IEC) complies 
with the requirements of 21 CFR  Part 56, and other applicable regulations, and 
conducts initial and ongoing reviews and approvals of the study. He or she will 
also ensure that any change in research activity and all problems involving risks to human subjects or others are reported to the IRB/IEC. Additionally, he or she 
will not make any changes in the research without IRB/IEC approval, except where necessary to eliminate apparent immediate hazards to human subjects.  
â€¢ He or she agrees to comply with all other requirements regarding the obligations 
of clinical investigators and all other pertinent requirements in 21  CFR Part 312. 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 64 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  9.2. Institutional Review Board/Independent Ethics Committee  
Before beginning study- specific research, the investigator will obtain written confirmation 
that the IRB, IEC , or Research Ethics Board (REB) is properly constituted and compliant 
with ICH and good clinical practice ( GCP) requirements, applicable laws, and local 
regulations. A copy of the confirmation from the IRB/IEC/REB will be provided to the 
Sponsor or its de signee. The protocol, informed consent form (ICF), IB, and any other 
appropriate written information provided to the subjects that the IRB/IEC/REB may require to fulfill its responsibilities will be submitted to the IRB/IEC/REB in advance of the study . 
The Sponsor or its designee must approve the ICF and all subject recruitment materials 
before they are submitted to the IRB/IEC/REB . The study will not proceed until appropriate 
documents from the IRB/IEC/REB confirming unconditional approval of the protocol and the ICF are obtained by the investigator and copies are received by the Sponsor or its 
designee. If possible, the approval document should refer to the study by study protocol title and the Sponsor study number, identify the documents reviewed, and inc lude the date of the 
review and approval. The written approval of the IRB/IEC/REB will be retained as part of 
the study file . The study may proceed before approval of consent forms and other study 
documents translated to a language other than the native la nguage of the clinical site, 
provided that written IRB/IEC/REB approval of the translated documents is obtained before they are used . Any amendments to the protocol should be reviewed promptly. 
The investigator must provide the appropriate periodic reports on the progress of the study to 
the IRB/IEC/REB and the Sponsor in accordance with local IRB/IEC/REB requirements and 
applicable governmental regulations, whichever is strictest.  
9.3. Informed Consent  
A properly written and executed ICF, in compliance with ICH E6 (GCP Guideline, 
Section 4.8), 21 CFR  Â§50, and other applicable local regulations, will be obtained for each 
subject before enrollment of the subject into the study. The investigator will prepare the ICF or revise the template ICF and provide the documents to the Sponsor (or designee) for 
approval before submission to the IRB/IEC/REB. The Sponsor and the IRB/IEC/REB must approve the documents before they are implemented.  
The investigator will provide copies of the signed ICF to each subject (or the subje ctâ€™s 
legally authorized representative) and will maintain the original in the subjectâ€™s record file.  
9.4. Data Recording and Quality Assurance  
As used in this protocol, the term case report form (CRF) should be understood to refer to 
either a paper form or an electronic data record or both, depending on the data collection 
method used. 
A CRF (approved by the Sponsor ) is required and should be completed (in English) for each 
randomized subject. The investigator has ultimate responsibility for the accuracy, 
authenticity, completeness, and timely collection and reporting of all clinical, safety, and 
laboratory data entered on the CRFs and any other data collection forms . The investigator 
must review and sign the CRFs to attest that the data contained on the CRFs are correct.  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 65 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  Electronic data capture (EDC) technology will be used for this study. All clinical information 
requested in this protocol will be recorded on the electronic case report forms approved by 
the Sponsor, or via other data collection methods, e.g., electronic laboratory data transfer . 
Study site personnel will enter (in English) study data into the CRFs for each randomized 
subject. Training on the EDC application will be completed and documented before access to 
the EDC system is given.  
In the event of a CRF data change ( e.g., correction of an error or addition of new 
information), corrections will be made to the CRF. Corrections to the CRFs, including the 
reason for change, will be automatically documented through the EDC systemâ€™s audit trail. 
The investigator is responsible for reviewing all CRFs, verifying them for accuracy, and 
approving them via an electronic signature. The investigator is designated as the signatory 
coordinating investigator. 
An electronic copy of the CRF casebooks will be sent to the site for retention with other 
study documents after full completion of the study, i.e., after database lock.  
The investigator is responsible for maintaining accurate, authentic, complete, and up- to-date 
records for each subject. The investigator is also responsible for ensuring the availability of any original source documentation related to the study (including any films, tracings, 
computer discs, tapes, and worksheets). In most cases the source is the subjectâ€™s medical 
record. Data collected on the CRFs must match the source documents. 
In some cases, the CRF may also serve as the source document . In these cases, a document 
should be available at the investigatorâ€™s site and clearly identify those data that will be 
recorded in the CRF and for which the CRF will stand as the source document. 
9.5. Document Retention  
Until otherwise notified by the Sponsor , an investigative site must retain in a controlled 
manner all study documents required by the Sponsor and by the applicable regulations. The investigative site must take measures to prevent accidental or premature destruction of 
essential documents, that is, documents that individually and collectively permit evaluation 
of the conduct of a study and the quality of the data produced, including paper copies of 
study records ( e.g., subject charts) and any original source documents that are electronic, as 
required by applicable regulations. 
The investigator must consult the Sponsor representative before disposal of any study records 
and must notify the Sponsor of any change in the location or disposition of the study files. If 
an investigator retires, relocates, or for other reasons withdraws from the responsibility of 
keeping the study documents, custody must be transferred to a person who will accept the 
responsibility. The Sponsor must be notified in writing of the name and address of the new 
custodian and must approve this transfer of responsibility. 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 66 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  9.6. Confidentiality  
The investigator or designee must explain to each subject, before enrollment into the study, 
that, for evaluation of study results, the subjectâ€™s confidential medical information obtained 
during the study may be shared with the study sponsor, the study sponsorâ€™s affiliated 
companies, the study sponsorâ€™s designated service providers, regulatory agencies, and the institutional review board (IRB) or independent ethics committee (IEC) . The investigator 
(or designee) is responsible for obtaining written permission to use confidential medical information in accordance with country- specific regulations (such  as the Health Insurance 
Portability and Accountability Act in the United  States) from each subject or, if appropriate, 
the subjectâ€™s legally authorized representative. If permission to use confidential medical 
information is withdrawn, the investigator is  responsible for documenting that no further data 
from the subject will be collected.  
Subject medical information obtained during this study is confidential, and disclosure to unauthorized third parties is prohibited. The pertinent sections of data protect ion laws will be 
complied with in full. Study records containing subject information will only be identified by 
the subject identification number, subject initials, date of birth, and study number, and not by 
the subjectâ€™s full name, except the subject con sent form, which is archived at the study center 
only. The subjectâ€™s name will not be used in any public report of the study. 
During the course of the study, a confidential subject identification list will be maintained by 
the investigator and archived at the investigative site.  
Before and during the conduct of the study, no study- related details may be  disclosed, 
i.e., placed on the internet, published, or otherwise publicized, or provided to a third party 
without prior written permission from the Sponsor. The policy for publication of data after 
completion of the study is described in Section  9.9 (Publication). 
9.7. Access to Data and Documents  
Upon receipt of the subjectâ€™s permission, medical information may be given to his or her 
personal physician or other appropriate medical personnel responsible for his or her welfare. 
Study data recorded on the CRFs must be verifiable to the source data. All original 
recordings, laboratory reports, and subject records generated by this study must be available 
to the Sponsor , representatives of the Sponsor, the IRB/IEC/REB, and applicable regulatory 
authorities, and they may be used for submission to regulatory authorities . In addition, all 
source data should be attributable (signed and dated), consistent with local medical practice. The investigator must therefore agree to allow direct access to all source data. Subjects 
(or their legally authorized representatives) must also allow access to their medical records, and subjects will be informed of this and will confirm their agreement when giving informed 
consent. 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 67 of 70 
 
Confidential â€“ Property of Theravance Biopharma, Inc.  9.8. Quality Control: Study Monitoring and Auditing  
Qualified individuals designated by the Sponsor will monitor all aspects of the study 
according to GCP and standard operating procedures (SOPs) for compliance with applicable 
government regulations. The investigator agrees to allow these monitors direct access to the 
clinical data and supplies, dispensing, and storage areas and, if requested, agrees to assist the monitors. The investigator and staff are responsible for being present or available for 
consultation during routinely scheduled site visits conducted by the Sponsor or its designees.  
Members of the Sp onsorâ€™s GCP Quality Assurance Department or designees may conduct an 
audit of a clinical site at any time during or after completion of the study. The investigator will be informed if an audit is to take place and advised as to the scope of the audit. 
Inspections and audits are typically carried out during the clinical and reporting phases of this 
study to ensure that the study is conducted and data are generated, documented, and reported 
in compliance with the protocol, GCP, written SOPs and applicable laws, rules, and 
regulations. 
Representatives of the FDA or other Regulatory Agencies, including IRB/IEC 
representatives may also conduct an audit of the study. If informed of such an inspection, the 
investigator should notify the Sponsor immediately . The investigator will ensure that the 
auditors have access to the clinical supplies, study site facilities, laboratory and all data 
(including original source documentation) and all study files are available, if requested. 
Noncompliance with the protocol, ICH, GCP, or local regulatory requirements by an 
investigator, institution, institution staff, or representatives of the Sponsor will lead to prompt 
action by the Sponsor to secure compliance. Continued noncompliance may result in 
termination of the investigatorâ€™ s involvement in the study. The IRB/IEC/REB and relevant 
regulatory authority will be informed. 
9.9. Publication  
The Sponsor recognizes the importance of communicating medical study data and therefore 
encourages their publication in reputable scientific journals and presentation at seminars or 
conferences . The Sponsor will retain the ownership of the data collected in this study . The 
investigator will provide any proposed manuscript or abstract to the Sponsor before 
submission for publication or presentation of any results or data obtained in this study. 
Additional details of the processes of producing and reviewing reports, manuscripts, and 
presentations based on the data from this study will be described in the Clinical Study 
Agreement between the Sponsor  and the investigator. 
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 68 of 70 
Confide
ntial â€“ Property of Theravance Biopharma, Inc.  10. REFERENCES
1. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the
diagnosis, management and prevention of chronic obstructive pulmonary disease.
2017. Available at: http://goldcopd.com
2. Miller, MR, Hankinson, J, Brusasco, V, Burgos, F, Casaburi, R, Coates, A, &
Wanger. Standardisation of spirometry. Eur Respir J, 2005:26(2), 319-38.
3.Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield
MT, Pavord I, Barnes
 N. A phase III randomised controlled trial of single-dose triple
the
rapy in COPD: the IMPACT protocol 2016
Available at: https://www.ncbi.nlm.nih.gov/pubmed/27418551
The above references are available upon request.  
Protocol 0167, Amendment 1  Version 1.0, 16APR2018  
Revefenacin  Page 69 of 70 
Confi
dential â€“ Property of Theravance Biopharma, Inc.  11. APPENDICES
Protocol 0167, Amendment 1 Version 1.0, 16APR2018  
Revefenacin  Page 70 of 70 
Confide
ntial â€“ Property of Theravance Biopharma, Inc.  APPENDIX 1. PROTOCOL SIGNATURE FORM  
Protocol Signature Form 
Protocol #: 0167 
Protocol Title:   A Phase 3b, 42 -day, Randomized, Double -Blind, Placeboâˆ’Controlled,  
Parallel Group Study to Evaluate the Safety and Tolerability of 
Nebulized Revefenacin and Nebulized Formoterol Fumarate 
Administered in Sequence and as a Combined 
Solution in Subjects with Chronic Obstructive Pulmonary Disease 
Version: 1.0 
Version Date:  16 April 2018, Amendment 1  
I have read the protocol described above and agree to conduct this study in accordance with procedures described therein.  I also agree to conduct the study in compliance with all applicable regulations. 
Investigatorâ€™s Name (print)  
Investigatorâ€™s Signature  Date 
